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CHAPTER ONE
STATEMENT OF THE PROBLEM
17β-estradiol (E2), the primary sex hormone in women, is important for many
physiological processes including those regulating normal brain function. The abrupt
decline of E2 in perimenopause is often accompanied by negative symptoms such as
changes in mood and cognition, as well as an increased risk for neurodegeneration.
Hormone replacement therapy (HRT) has been introduced to replenish levels of E2 in
circulation; however, recent clinical trials have revealed a critical window directly
following the onset of menopause in which E2 supplementation is efficacious.
Alarmingly, administration of E2 later than 10 years after menopausal onset was linked
to a variety of adverse clinical outcomes. Specifically, in the brain, late E2
supplementation was found to exacerbate age-related dementia. This was seemingly
contradictory to findings from animal models which generally support a neuroprotective
role of E2 in the brain. These time-dependent, disparate effects of HRT, termed the
‘timing hypothesis’, have since been investigated in animal models to elucidate the
molecular mechanisms underlying this switch in E2 action.
MicroRNAs, a class of small non-coding RNAs that regulate gene expression,
are a putative target underlying the ‘timing hypothesis’. Previous research in our lab has
identified E2-responsive miRNAs in the aging rat brain. Among these were miR-9-5p
and -3p, which have well documented roles as potent regulators of neurogenesis,
dendritic outgrowth, and synaptic plasticity. Furthermore, dysregulation of miR-9-5p and
1
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-3p in the brain have been linked to pathologies such as Alzheimer’s disease and
glioma formation. Taken together, these data indicate that the fine-tuning of miR-9-5p
and -3p expression is critical for neuronal maintenance and health. However, it is still
unclear as to the mechanism of how HRT (i.e. E2) can differentially regulate miR-9-5p
and -3p, especially in the context of the aging brain. Therefore, the central hypothesis
for this dissertation is that E2 regulates miR-9-5p and -3p through stabilization and
differential localization of the mature transcripts in an age dependent manner. The goal
of this dissertation is to further elucidate a miRNA-mediated mechanism of the
molecular switch that underlies hormone-responsive health in the postmenopausal
brain. This hypothesis was tested by pursuing the following 2 aims.
Aim 1. Measure stabilization of miR-9-5p and -3p following E2 administration in
the aging female brain.
miRNAs are potent regulators of many cellular processes, and their regulation
can occur at multiple points along the biogenesis pathway. Previous data indicated that
E2-mediated increases in the levels of mature miR-9-5p and -3p did not coincide with
increases in their respective primary and precursor transcripts, suggesting that E2 is not
upregulating miRNA transcription. Therefore, my working hypothesis was that E2
administration stabilizes mature miR-9-5p and -3p in early menopause, but this
stabilization would be absent in late menopause. miRNA stabilization was tested in
various model systems using radiolabeled oligonucleotides with the same nucleotide
sequence as miR-9-5p and -3p. First, a rat hypothalamic neuronal cell line was used to
investigate the impact of acute E2 treatment on the stabilization of miR-9-5p and -3p.
The complexities of the ‘timing hypothesis’ necessitated an animal model of menopause
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to determine whether E2-mediated miRNA stabilization changes with the timing of E2
administration. Therefore, aged rats were ovariectomized and given HRT (i.e. E2) after
varying lengths of E2 deprivation, and hypothalamic tissue lysate from these aged rats
was used for the miRNA degradation assay.
Aim 2. Quantify differences in the cytoplasmic and nuclear levels of miR-9-5p and
miR-9-3p following E2 administration.
Canonically, miRNAs are thought to exert their regulatory effects in the
cytoplasm upon their recruitment to an RNA-induced silencing complex. However,
recent studies have shown that mature miRNAs can also be found in the nucleus, and it
is likely that these nuclear miRNAs have different downstream effects compared to their
cytoplasmic counterparts. While dysregulation of miRNA abundance can have a
profound impact on target mRNA expression, alteration of miRNA localization can add
another layer of regulation that underlies the miRNA-mediated, molecular switch of E2
action. Therefore, my working hypothesis was that more miR-9-5p and -3p will be
localized in the cytoplasm following E2 treatment. The rationale for this hypothesis was
based off of evidence from the literature suggesting that miR-9-5p and miR-9-3p have
critical roles in maintaining neuronal health in the cytoplasm. Subcellular fractionation
and RT-qPCR was utilized in the model systems described above to determine the
impact of E2 treatment and deprivation on miR-9-5p and -3p localization.
These studies are innovative, because it investigates, for the first time, hormonal
regulation of miRNA stability and subcellular localization within the context of the aging
brain. These studies allow for a clearer understanding of the molecular mechanism that
underlies the age-dependent efficacy of hormone replacement therapy.

CHAPTER TWO
LITERATURE REVIEW
Menopause and the Timing Hypothesis
According to the Global Health Observatory (GHO), women have a life
expectancy of approximately 74 years of age. About a third of the female lifespan is
spent with low levels of circulating estrogens such as 17β-estradiol (E2), the
predominant estrogen during reproductive years. Levels of E2 gradually decline
following the onset of menopause (around the age of 50) and remains low for the
remainder of the lifespan. This absence of E2 in circulation is potentially problematic,
due to the protective effects of E2 that have been described in the regulation of normal
physiology, particularly in the central nervous system (Iorga et al, 2017, Brown et al.,
2009). The absence of E2 in the brain during menopause, for instance, is a potential
contributing factor for the sex-specific increase in risk for Alzheimer disease (Mielke,
2019). Accordingly, estrogen deficiency in the brain has been linked to poor cerebral
perfusion, memory impairment, and mood disturbances, which over time can manifest in
long term cognitive impairment (Zaw et al., 2019).
Therefore, hormone replacement therapy (HRT) was introduced as a clinical
strategy to replenish circulating levels of E2 in efforts to retain its protective effects. In
1997, the Women’s Health Initiative (WHI) initiated a large-scale study assessing the
health risks and benefits of HRT. Briefly, postmenopausal women around the ages of
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50-79 (average age of 63) were given oral conjugated equine estrogen (CEE) with or
without medroxyprogesterone acetate (MPA). MPA is an artificial compound that mimics
the actions of endogenous progesterone; this steroid was given in conjunction to CEE to
lower the risk of endometrial cancer which can result from uncontrolled E2 activity in
women with an intact uterus. Subsequently, various clinical endpoints were evaluated in
these women to determine the efficacy of HRT.
The results of the study, however, were alarming. Women who received
treatment (CEE and MPA) exhibited higher risk for coronary heart disease, breast
cancer, and stroke (Rossouw, 2002). These health risks seemingly outweighed the
benefits of lowered risk for colorectal cancer and diabetes. In the brain, the Women’s
Health Initiative Memory Study (WHIMS) investigated the effect of HRT on global
cognitive function (Shumaker et al 2004), and treatment was found to be associated
with an increased risk for dementia. Furthermore, the Women’s Health Initiative for
Cognitive Aging (WHISCA) determined that verbal memory on a neuropsychological
assessment declined with CEE and MPA treatment (Resnick et al., 2006). Therefore,
this study was terminated early with the recommendation that hormone replacement
therapy (HRT) should no longer be offered as a clinical treatment to alleviate the
symptoms of menopause. Accordingly, it has been estimated that the incidence of HRT
dropped 40~80% within months following the publication of these findings (Burger et al
2012).
However, subsequent reanalysis of data published from the WHI with age-based
stratification revealed that the effects of HRT may be dependent on the timing of
administration. Specifically, HRT that was initiated soon after menopause was largely

6
beneficial in contrast to late administration (Table 1). This was termed the “timing
hypothesis”, as the efficacy of HRT seemed to be restricted to a critical window of time
10 years from the onset of menopause. Early treatment was associated with reduced
mortality, lower incidence of heart failure, with no increase in the risk for stroke. In the
Kronos Early Estrogen Prevention Study (KEEPS), women were treated within 2 years
of menopausal onset (ages 42-58), and early administration was associated with
improved bone mineral density and insulin sensitivity (Harman et al., 2005) (Wharton et
al., 2013). The Research into Memory, Brain Function, and Estrogen Replacement
(REMEMBER) study found that when HRT was initiated before the age of 56,
performance on examinations assessing information processing and verbal fluency was
significantly improved over the placebo controls (MacLennan et al., 2006). Additional
observational studies indicated a neuroprotective effect of HRT early in menopause, but
increased risk of dementia and cognitive decline in late menopause (ages 65-79)
(Leblanc et al 2001, Waring et al 1999). These studies all supported the occurrence of a
temporal switch in the molecular actions of HRT, especially in the context of the central
nervous system.
Table 1. Health Risks and Benefits of Hormone Replacement Therapy Stratified by
Age of Treatment.
Early Treatment

Ages ( < 60)

Late Treatment

Ages ( > 60)

Benefits
(Lowered risk of)

Mortality,
Diabetes,
Dementia,
Osteoporosis,
Heart Disease
Cancer (slight)

Benefits
(Lowered risk of)

Diabetes,
Osteoporosis,

Risks
(Increased risk of)

Stroke,
Cancer,
Dementia,
Heart Disease

Risks
(Increased risk of)
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Estrogen Receptor Signaling Mechanisms
Estrogens are a class of female sex hormones that have pleiotropic effects in
various areas of physiology including the regulation of bone density, inflammation, and
brain function (Santen et al., 2019). However, estrogens have primarily been linked to
the regulation of the female reproductive system and the development of secondary sex
characteristics. There are three different estrogens in circulation: estrone (E1), estradiol
(E2), and estriol (E3). E3 is elevated during pregnancy, E1 is higher during menopause,
and E2 is the predominant circulating estrogen during the reproductive years. All of
these estrogens are synthesized in the ovaries from cholesterol into an 18-carbon
aromatic structure that is hydrophobic in nature. This hydrophobicity allows for these
hormones to diffuse across the plasma membrane to bind estrogen receptors (ERs).
These estrogen receptors subsequently dimerize and translocate into the nucleus to
regulate the transcription of downstream genes. Transcriptional regulation occurs upon
the interaction of ERs with estrogen response elements (EREs) in enhancer regions
close to the gene promoters. The consensus ERE sequence is a palindrome
(GGTCANNNTGACC), and it has been estimated that there are over 70,000 EREs in
the human genome, underscoring the importance of the estrogen signaling in the
regulation of transcription (Bourdeau et al., 2004). ERE-bound ERs recruit coregulators,
which act as integrators to either activate or inhibit gene transcription. Estrogens can
also have non-genomic effects by activating second messenger pathways by binding to
membrane bound ERs or G-protein coupled estrogen receptors (GPER30).
There are two classical endogenous estrogen receptors, ER and ER, which
can have divergent functions (Lee et al., 2012). Both ERs have been associated with
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reproductive function, although ER seems to be primarily responsible. ER KO
animals are infertile with a hypotrophic uterus, whereas ER KO animals are subfertile,
with impairment in ovulatory processes (Hewitt et al., 2016). Also, in both breast and
prostate cancer, ER signaling favors cancer progression while ER signaling was
associated with more protective, pro-apoptotic processes (Omoto et al., 2015). These
studies suggest that each receptor could have overlapping functions in the regulation of
female reproduction but opposing functions in other cellular contexts such as disease.
Molecular Changes in the Brain with Aging and E2 Treatment
In a rat ovariectomy model of menopause, distinct molecular patterns were
observed dependent on the timing of E2 administration. E2 can exert its effects by the
activation of second messenger pathways and intermediate signaling proteins such as
mitogen activated protein kinases (MAPK). Two MAPK family members, p38 and ERK,
were found to be significantly regulated by both age and E2 treatment in a brain region
specific manner (Pinceti et al., 2016). Therefore, the differential regulation of MAPK
signaling, both in terms of kinase expression and activation status, could be one
component that could underlie the molecular switch in E2 efficacy dependent on age.
Furthermore, the expression of ER splice variants was also significantly altered by age
and E2 in this model (Shults et al., 2015). A potential mechanism for the differential
production of ER isoforms was the alteration of global transcriptional activity, which
was measured by the expression phosphorylated RNA polymerase II (Shults et al.,
2015). Alternatively, E2 was also shown to regulate the splicing protein NOVA1, which
in turn regulated the expression of the ER2 splice variant (Shults et al., 2018). As
splice variants can have altered downstream functions from the wildtype, this
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mechanism provides another molecular explanation for the disparate actions of E2
dependent on age.
MiRNA Biogenesis
The differential regulation of miRNAs in the brain can also contribute to the
distinct molecular patterns observed following E2 administration. miRNAs are a
subfamily of noncoding RNAs that post-transcriptionally regulate gene expression. The
mature miRNA, between 20 and 24 nucleotides in length, binds to complementary
sequences in the 3’ UTR of target mRNAs to either cause endonucleolytic cleavage or
to repress translation. Endonucleolytic cleavage of the target mRNA is frequently
observed in plants whereas translational repression of the target mRNA seems to be
the predominant mode of regulation in metazoans (Ameres et al., 2013).
miRNAs are transcribed in the nucleus by RNA polymerase II (RNA Pol II) into
long primary miRNAs (pri-miRNA), which typically contain a stem loop region, a 5’ cap,
and a 3’ poly-A tail (Fig. 1). Pri-miRNAs are generally transcribed independently through
their own promoter interactions with the canonical transcriptional machinery; however,
some miRNAs arise from the introns of protein coding genes. Once transcribed, primiRNAs are processed by the microprocessor complex which consists of the
endonuclease Drosha and a cofactor called DiGeorge Syndrome Critical Region 8
(DGCR8) (Gregory et al., 2004). DGCR8 is critical for pri-miRNA recognition by Drosha
(Han et al., 2004). The C-terminus of DGCR8 contains a protein-protein interaction
domain which allows it to bind to Drosha and two double-stranded RNA binding
domains (dsRBD) which recognize and interact with pri-miRNAs (Denli et al., 2004).
Drosha is a nuclear endonuclease specific for double-stranded RNA sequences. It
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contains two RNase III domains (RIIIDs) that sequentially cleave the 5’ lower stem and
the 3’ overhang of the pri-miRNA. Once the recognition and cleavage of the pri-miRNA
is complete, the resulting structure is precursor miRNA, or pre-miRNA. Pre-miRNA is
then transported to the cytoplasm by exportin 5 which forms a complex with Ran, a Ras
related GTPase (Yi et al., 2003; Fig. 1).
Once in the cytoplasm, the pre-miRNA is then cleaved once more by another
RNase III enzyme called Dicer (Fig. 1). Dicer has an N-terminal helicase domain that
interacts with the stem loop of the pre-miRNA to facilitate recognition (Ketting et al.,
2001). Similarly, the PAZ (Piwi-Ago-ZWILLE) domain facilitates the recognition and
binding of the terminal ends of the pre-miRNA (Macrae et al., 2006). Once the precursor
is successfully bound, tandem RIIIDs of Dicer cleave the stem loop region producing a
miRNA-miRNA* duplex which consists of approximately 45 nucleotides. This duplex is
then loaded onto an argonaute protein (AGO) via an ATP-dependent process, and
RISC, or RNA induced silencing complex, is subsequently assembled. Four different
AGO proteins (AGO 1-4) exist, but only AGO2 contains an active site on its PIWI
domain that can endonucleolytically cleave the target mRNA (Huntzinger et al., 2011).
Following the loading of the miRNA duplex, unwinding occurs where the passenger
strand (miRNA*) is quickly removed and degraded. The resulting single stranded
sequence is termed the guide strand. In rare instances, AGO2 can cleave the
passenger strand, and the remnants are subsequently removed by the endonuclease
C3PO (Liu et al., 2009). Typically, however, the duplex is unwound first, and
degradation of the passenger strand occurs after its removal.
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The selection of the guide strand is determined by a set of specific, yet flexible,
criteria. For instance, the strand with the more thermodynamically unstable 5’ terminus
is generally selected as the guide strand (Khvorova et al., 2003). In addition, there is a
preference for uracil to be in the first nucleotide position when determining the guide
strand (Kawamata et al., 2009). However, the criteria for guide strand selection are not
necessarily absolute; there are instances where the unfavorable strand is chosen as the
guide strand. Since the passenger strand is degraded quickly upon its removal, the
relative abundance of the passenger strand is significantly lower compared to the guide
strand. The lower relative abundance, however, does not exclude the passenger strand
of its mRNA silencing function. While comparatively less potent in its silencing
capabilities, the passenger strand can still be involved in mRNA regulation (Chiang et
al., 2010).
Once the guide strand is determined, RISC facilitates the interaction of a seed
sequence on the 5’ end of the guide strand to its complementary mRNA sequence. The
seed sequence is only about 6 to 8 nucleotides in length and can therefore base pair
with hundreds of complementary mRNA targets. While complementary base pairing can
occur along all regions of the mRNA target, silencing activity is mostly observed when
the seed sequence binds to the target 3’ UTR (Bartel et al., 2009).
There are also other non-canonical pathways of miRNA biogenesis. For
example, the pri-miRNA cleavage step by the microprocessor complex can be
bypassed. miRtrons, or miRNAs located within introns, are formed directly from mRNA
splicing. The branched miRtron is then converted into a precursor-like structure by the
Lariat debranching enzyme (DBR1) (Babiarz et al., 2008). Likewise, processing of the
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precursor miRNA by Dicer can also be circumvented. For example, pre-miR-451 is
directly loaded onto RISC as its nucleotide sequence is too short to be recognized by
Dicer. Once loaded, pre-miR-451 is trimmed by ribonucleases to facilitate its maturation
(Cheloufi et al., 2010).
In addition to these non-canonical pathways, there are still other processes that
can introduce variations to miRNA biogenesis and development. For instance, isomiRs,
or miRNA isoforms, exhibit sequence heterogeneity introduced not only by imprecise
cleavage, but also by the addition of nucleotides. Dicer, for example, can cleave the
precursor form at varying sites resulting in a diverse array of duplexes with different
seed nucleotide arrangements (Berezikov et al., 2011). As a consequence, these
differences in the 5’ end seed sequence can then alter the range of interactions with
potential mRNA targets.
The seed sequences can also be changed by the ADAR (adenosine deaminase
acting on RNA) enzyme. As its name suggests, ADAR facilitates the conversion of
adenosine to inosine. Interestingly, ADAR is primarily expressed in neural tissue
suggesting that miRNAs in the brain are more frequently edited compared to other
tissues (Hundley et al., 2010). In Drosophila, mature miRNAs can also be trimmed from
the 3’ end by an enzyme called Nibbler (Liu et al., 2011). Similarly, in humans, a
Nibbler-like exoribonuclease trims the 3’ end of mature miRNAs to alter its sequence
(Han et al., 2011). The function of 3’ end trimming is not entirely understood, since the
seed sequence which is important for target binding is located in the 5’ end. However, it
has been proposed that 3’ end trimming could alter the degradation kinetics of the
mature miRNA and thereby the duration of target mRNA repression. Finally, 3’
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heterogeneity can also arise from the addition of nucleotides to the 3’ end by TNTases,
or terminal nucleotidyl transferases (Rissland et al., 2007). This 3’ tailing process,
especially uridylation and polyadenylation, seems to be important for miRNA turnover.

Figure 1. MiRNA Biogenesis Pathway
Regulation of MiRNA Biogenesis
Every step of the miRNA biogenesis pathway can be regulated. As with coding
RNA, transcription of miRNA is initiated by various transcription factors interacting with
the promotor region. Multiple miRNAs can be transcribed from the same promotor;
these miRNAs form a miRNA cluster (Lee et al., 2002). MYC and p53, transcription
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factors important for mRNA transcription, can also drive the transcription of miRNA
clusters. However, there seems to be specificity of MYC and p53 for particular miRNAs,
as binding to some promotor regions induce activation while others induce repression.
For example, MYC activates the miR-17 cluster, but generally inhibits the transcription
of the miR-15a cluster (Krol et al., 2010). Finally, miRNA transcription can also be
regulated by epigenetic means, namely DNA methylation and histone modification
(Davis-Dusenbery et al., 2010).
miRNA biogenesis can also be regulated at the microprocessor step. Since the
Drosha:DGCR8 complex is critical for pri-miR cleavage to the precursor form, regulation
of this complex can lead to profound changes in miRNA abundance and processing
activity (Han et al., 2009). For instance, there are various post-translational
modifications of Drosha that can regulate its localization and function. GSK3β, or
glycogen synthase kinase 3β, can phosphorylate Drosha, and this particular
modification is required for its nuclear localization (Tang et al., 2010). Drosha can also
be stabilized when acetylated or when bound to TDP43, or TAR DNA-binding protein 43
(Di Carlo et al., 2013). Similarly, DGCR8 can also be post-translationally modified. For
example, ERK can phosphorylate DGCR8 to promote its stability, and HDAC1, or
histone deacetylase 1, can deacetylate DGCR8 to increase its binding affinity to primiRNAs (Herbert et al., 2013). Finally, recent studies have shown that phosphorylated
MECP2, or methyl-CpG-binding protein 2, can bind to and sequester DGCR8 inhibiting
its association with Drosha (Cheng et al., 2014).
The efficiency of Drosha processing can also be regulated by its association with
RNA-binding proteins such as p68 and p72: Drosha interaction with the SMAD, p53,
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and p68 complex was shown to enhance pri-miRNA processing. (Davis et al., 2008).
Other RNA-binding proteins, such as KSRP and HNRNPA1, can also bind to the
terminal loop of pri-miRNAs to further facilitate Drosha mediated cleavage (Trabucchi et
al., 2009). Dicer processing can also be regulated by RNA-binding proteins. KSRP (KHtype splicing regulatory protein), which is important in Drosha-mediated processing, can
also stimulate Dicer activity by binding to the terminal loop region of precursor miRNAs.
In the case of let-7 pre-miRNA, LIN28 can compete with KSRP for the terminal loop
binding site; therefore, with LIN28 bound, dicing of let-7 pre-miRNA is inhibited which
ultimately leads to a decrease in mature let-7 abundance (Trabucchi et al., 2009).
In Drosophila, Dicer interacts with two Loquacious (Loqs) isoforms: Loqs-PA and LoqsPB. Both Loqs-PA and Loqs-PB interact with Dicer through their dsRBDs and are
generally required for the processing of pre-miRNA (Forstemann et al., 2005). In
contrast, human Dicer binds to two known dsRBD proteins: TRBP (TAR RNA-binding
protein) and PRKRA (protein kinase interferon-inducible double stranded RNA
dependent activator) (Garcia et al., 2007). TRBP, in turn, can be stabilized by ERK
phosphorylation which then can improve the duration and efficiency of Dicer processing
(Paroo et al., 2009).
Finally, miRNA biogenesis can also be regulated by post-translationally
modifying AGO proteins at the level of RISC assembly. C-P4H(I), or type I collagen
prolyl-hydroxylase, is thought to stabilize AGO2 through hydroxylation (Wu et al., 2011).
MAPK phosphorylation of AGO2 at Serine 387 facilitates the localization of AGO2 to
processing bodies where translational repression of mRNA targets is thought to occur
(Zeng et al., 2008). However, when AGO2 is phosphorylated at Tyrosine 529, its ability
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to bind miRNAs is significantly reduced (Rudel et al., 2011). Therefore, depending on
the site of phosphorylation, AGO function can be completely altered. AGO proteins can
also be ubiquitinated by E3 ubiquitin ligases to be targeted to the proteasome for
degradation (Rybak et al., 2009). The degradation of AGO proteins via the proteasome
pathway could ultimately affect mature miRNA stability as more miRNAs would be
unbound and exposed to various exonucleases that are present in the cytoplasm.
Estrogen Regulation of MiRNA
Interestingly, estrogen has been shown to regulate mature miRNA expression in
vivo. However, most of these studies have focused on E2’s effect on miRNA in the
context of breast cancer. In MCF-7 cells, a human breast cancer cell line, estrogen
decreased the expression of miR-206 (Adams et al., 2007). Another study utilized
microarrays to compare miRNA expression in MCF-7 cells following estrogen treatment
and found up to 38 miRNAs were differentially regulated by estrogen treatment (Pan et
al., 2008). Generally, widespread decreases in mature miRNA expression levels have
been reported upon estrogen treatment in various breast cancer cell lines (Maillot et al.,
2009).
However, there have been several miRNAs that have been identified to be
upregulated with E2 treatment. Specifically, Bhat-Nakshatri and colleagues found that
miR-let-7f and miR-98 showed robust increases of up to a 3-fold difference following
estrogen treatment. Interestingly, previous studies showed that E2 also mediated the
increased transcription of c-Myc and E2F2 mRNA, which are putative mRNA targets for
miR-let-7f and miR-98. Knockdown of miR-let-7f and miR-98 confirmed this target
interaction, supporting the notion that miR-let-7f and miR-98 act to counterbalance E2-
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mediated increases in c-Myc and E2F2 to maintain homeostasis (Bhat-Nakshatri et al.,
2009).
Additionally, chromatin immunoprecipitation (ChIP) assays were used to
determine that miR-21 had a regulatory region responsive to ERα, suggesting that E2
can directly upregulate pri-miR-21 transcription. Interestingly, it has also been shown
that Dicer mRNA can be upregulated through ERα-mediated transcription, potentially
introducing an additional layer of complexity involving pre-miRNA processing leading,
ultimately, to alterations in miRNA abundance (Bhat-Nakshatri et al., 2009).
Furthermore, miR-222, miR-221, and miR-29a levels were significantly increased in
ERα negative breast cancer cells. This finding was interesting, because these miRNAs
were shown to repress Dicer levels by binding to the 3’ UTR of Dicer1 mRNA. These
results taken together provide even more clarity as to why ERα negative breast cancer
cells express low levels of Dicer (Cochrane et al., 2010). Furthermore, some specific
miRNAs, such as miR-22, have been shown to directly target the 3’ UTR of ERα mRNA
to inhibit its translation. Consequently, the overexpression of miR-22 resulted in the
inhibition of ERα levels and thereby reduced ERα mediated estrogen signaling
pathways (Pandey et al., 2009). Therefore, it can be reasonably inferred that the
estrogen signaling pathway and the miRNA biogenesis pathway seem to be intricately
intertwined at various intersections—each pathway having the ability to regulate the
other.
Unfortunately, there have been few studies that have investigated estrogen
regulation of miRNA expression in a context removed from breast cancer research.
Recently, estrogen has been shown, in vivo, to differentially regulate neuronal miRNA
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expression in a brain region-specific manner (Rao et al., 2013). In this study, microarray
analysis revealed that 34 miRNAs were significantly regulated by estrogen treatment in
the ventral hippocampus. Interestingly, E2 had no effect on the processing enzymes in
the miRNA biogenesis pathway. The steady state levels of Drosha, Dicer, and AGO2
were not altered with estrogen treatment (Rao et al., 2013), suggesting that changes in
miRNA levels could be due to E2 acting directly at the promotor level by interacting with
estrogen receptors to potentiate pri-miRNA transcription. However, the E2 responsive
miRNAs were mostly altered at the mature level rather than at the primary or precursor
level (Rao et al., 2015), suggesting that E2 was not regulating miRNAs at the level of
transcription or processing. Therefore, the remaining possibility for the changes in
miRNA expression levels was likely to be further downstream—at the level of mature
miRNA stability.
MiRNA Degradation
Recent research on miRNA stability has primarily involved identifying key
enzymes that are part of the degradation process in both plants and animals. Certain
candidate nucleases, such as small RNA degrading nucleases (SDNs) have been
proposed to degrade miRNAs in Arabidopsis thaliana from the 3’-to-5’ direction
(Ramachandran et al., 2008). In Caenorhabditis elegans and in humans, the 5’-to-3’
exoribonuclease XRN-1, is critical for miRNA degradation (Chatterjee et al., 2011).
Recently, it has been revealed that a critical enzyme in miRNA degradation is the
decapping scavenger protein DCS-1. This finding was interesting due to the fact that
mature miRNAs, unlike mRNAs, do not have a 5’ cap. DCS-1 was important for another
reason—it recruited XRN1, an exoribonuclease, to the miRNA to initiate 5’ to 3’
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degradation (Bosse et al., 2013). Therefore, the vast array of unique enzymes found to
be important for miRNA degradation seem to oppose the notion of a general, widely
conserved pathway for miRNA degradation; rather, different organisms seem to rely on
distinct mechanisms of degradation.
Generally, it has been observed that miRNAs are globally more stable than
mRNA (Gantier et al., 2011). In addition, highly expressed miRNAs are correlated with a
higher rate of turnover whereas lowly expressed miRNAs seem to be relatively more
stable. miRNA turnover kinetics also varied with cell type, affirming the hypothesis that
miRNA stability is context dependent (Li et al., 2013).
The specific triggers that regulate the miRNA degradation process is, however,
still unclear. One intriguing possibility is that miRNA turnover is mediated by its mRNA
target. While mRNAs are generally thought to be translationally repressed or cleaved by
interacting with mature miRNAs loaded unto RISC, there have been studies that
suggest a reciprocal means of regulation where miRNA stability can be influenced by
mRNA as well. For instance, in HEK293T cells, miRNAs were degraded more rapidly
upon base pairing with highly complementary mRNA targets compared to pairing with
mRNA targets with less than 8 nucleotide lengths of complementarity (Ameres et al.,
2010).
Cell cycle progression has also been observed as a regulator of miRNA stability.
Specific cellular environments are thought to accelerate miRNA degradation, especially
during cell cycle transitional phases. A proposed mechanism of miRNA degradation
driving cell cycle progression closely mirrors the rapid induction and turnover of various
cyclins which activate CDKs, or cyclin dependent kinases, to initiate a signaling cascade

20
specific to different phases of the cell cycle. For instance, miR-29b was found to be
enriched in mitotic cells. The half-life of miR-29b was greater than 12 hours in mitotic
cells compared to approximately 4 hours in non-dividing cells (Zhang et al., 2012).
Some miRNAs are expressed constitutively at almost undetectable levels so that its
activity can be quickly abolished when necessary. An example of this is miR-503 which
was observed in growth arrested cells but became undetectable upon re-entry to the
cell cycle (Rissland et al., 2011). This finding was intuitive, as the factors important for
cell cycle progression, cyclin D1, cyclin E1, and CDK6, were all found to be putative
targets for miR-503.
Recently, there have been some interesting studies investigating the possibility of
miRNA turnover regulated by extracellular signals. For example, EGF (epidermal growth
factor) treatment rapidly decreased levels of 23 miRNAs in MCF10A breast epithelial
cells (Avraham et al., 2010). Common targets of these miRNAs included immediate
early genes and other growth promoting genes. These findings suggest that EGFmediated proliferation is activated partly by the rapid turnover of several growthinhibiting miRNAs. These studies, unfortunately, failed to differentiate between miRNA
degradation and repression of their expression.
Rapid turnover, however, seems to be a prevailing feature of miRNAs in neurons.
One study examined miRNA turnover in embryonic stem cells in relation to
differentiated pyramidal neurons and found rapid miRNA turnover in pyramidal neurons
but not in the undifferentiated state (Krol et al., 2010). miRNAs taken from primary
human neuronal cultures and from post-mortem brain tissues also exhibited significantly
shorter half-lives of less than three and a half hours, as compared to those reported in
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other non-differentiated cells (Sethi et al., 2009). This rapid turnover in neurons seems
to be dependent on neuronal activity. When tetrodotoxin was used to block action
potential formation, the rapid degradation of most miRNAs was prevented. The major
exception to this rule was miR-132 which experienced rapid decay when glutamate
receptors were experimentally blocked (Krol et al., 2010). Otherwise, a positive
correlation between neuronal activity and rapid miRNA decay was observed. Another
study reported that XRN-2 and PAPD4—an exoribonuclease and a poly-A polymerase
important for miRNA degradation—were expressed weakly in immature neurons, but
levels seemed to accumulate as maturation occurred. Interestingly, XRN-2 and PAPD4
levels were virtually nonexistent in glial and endothelial cells, supporting the notion that
neurons are distinct in their characteristic of having higher rates of miRNA degradation
(Kinjo et al., 2013).
Post-transcriptional modifications to the miRNA are another way stability can be
regulated. In HEK293 cells, knockdown of the m6A demethylase, FTO, resulted in the
steady state level change of 17 miRNAs, implying that methylation of adenosine could
be important in determining the stability of a subset of miRNAs (Berulava et al., 2015).
In plants, the 3’ end of miRNAs is methylated by the methyltransferase HEN1. This
methylation offers effective, albeit incomplete, protection from being degraded by small
RNA degrading nucleases (SDNs) (Li et al., 2005).
Oligouridylation, where 10 to 30 nucleotides are added to the 3’ end of the
miRNA by the terminal nucleotidyl transferase HESO1, accelerated miRNA degradation
by SDNs, suggesting that uridylation either promoted the assembly of the degradation
machinery or provided the fully formed machinery with a more preferable docking site
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(Zhao et al., 2012). A similar effect of instability mediated by uridylation can be seen in
Chlamydomonas reinhardtii where a different terminal nucleotidyl transferase called
MUT68 is responsible for uridylating the 3’ ends of miRNAs. Unsurprisingly, this
uridylation promoted degradation of the miRNA by RRP6, or ribosomal RNA processing
protein 6 (Ibrahim et al., 2010). For human miRNAs, however, a different effect was
seen upon uridylation. The nucleotidyl transferase TUTase 4 was found to uridylate
miR-26a in human lung alveolar epithelial cells. However, uridylation did not affect miR26 degradation kinetics; rather, there was a reduction in the efficacy of miR-26a’s
inhibitory effects on its target interleukin-6 (Jones et al., 2009). To add another layer of
complexity, precursor miRNAs were shown to be uridylated as well, and depending on
the specific context of uridylation, the effects of uridylation were vastly different.
Oligouridylation of the pre-miRNA by TUT4 inhibited miRNA biogenesis whereas
monouridylation seemed to promote miRNA biogenesis. Interestingly, when the 3’ end
of the precursor was trimmed by a nuclease prior to uridylation by TUT4, the pre-miRNA
was more prone to degradation (Kim et al., 2015). Therefore, the consequences of
uridylation on miRNA stability seem to be heavily dependent on both species and
context.
While polyadenylation has not been studied as extensively as uridylation with
respect to miRNA turnover, post-transcriptional modifications involving polyadenylation
seem to also be context dependent. miR-122, expressed in hepatocytes, was stabilized
upon adenylation; however, adenylation of miRNAs by the virally encoded VP55 protein
resulted in rapid decay (Katoh et al., 2009).

23
Recent research has also illuminated the ability of viruses to employ an
interesting method to destabilize host miRNAs. For instance, Herpesvirus saimiri can
encode several non-coding RNAs that can base pair with miR-27a. Specifically, HSUR1
(Herpesvirus saimiri U RNA) was found to interact with the seed sequence of miR-27a
to promote its degradation (Cazalla et al., 2010). This intriguing finding sheds light on
how specific miRNAs can be targeted for degradation to elicit a preferred cellular
response—namely, the apparent viral inhibition of a host cell’s defense system.
These previous studies have revealed various mechanisms by which miRNA
stability can be regulated. Both the biogenesis and degradation of many miRNAs can be
specifically targeted, and its effects seem to rely heavily on the context of the cellular
and physiological environment. As the field of miRNA research moves forward, the
mechanisms of regulation and extracellular cues that negate or potentiate miRNA
degradation must be better elucidated. The present research investigated the role of E2
in the regulation of miRNA degradation and introduced hormonal triggers that can elicit
differential effects on the turnover of a specific subset of miRNAs.
Rapid MiRNA Degradation Kinetics in the Brain
In general, mature miRNAs are relatively stable in mammalian systems where
they exhibit half-lives in the hours timescale (Guo et al., 2015, Kingston et al., 2019, Li
et al., 2013, Reichholf et al., 2019). This stability is thought to be imparted by its
association with a multi-protein complex called RISC. Structural analyses revealed that
the miRNA 5’ and 3’ ends are embedded into an Argonaute (AGO) protein, an RNA
binding component of RISC, and protects the miRNA from cellular exoribonucleases
(RNases) (Sheu-Gruttadauria et al., 2019, Wang et al., 2008). Notably, the central
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nervous system represents a striking exception to the global stability of miRNAs in other
tissues. Various reports have shown that miRNA degradation kinetics are extremely
rapid (in the timescale of minutes to hours) in neurons (De La Mata et al., 2015, Kim et
al., 2020, Sethi et al., 2009). For instance, Krol and colleagues reported that the miRNA
cluster miR-183/96/182 was regulated by light/dark stimuli, and their levels were
drastically altered within ~90 mins in retinal neurons by the combination of rapid decay
and increased transcription (Krol et al., 2010). Moreover, neuronal miRNAs that were
not regulated by light, such as miR-15,-16, and 29c, still exhibited rapid turnover,
suggesting that the rapid kinetics were an intrinsic property of these neuronal miRNAs
(Krol et al., 2010).
These findings were later corroborated in other neuronal model systems. For
instance, neuronally enriched miR-9-5p and miR-9-3p, which are derived from the 5’
and 3’ arms of the miRNA precursor respectively, were degraded in the minutes times
scale in a rat hypothalamic cell line (IVB) and in multiple brain regions (Kim et al., 2020).
Rapid miRNA turnover was also reported in primary neuronal cultures and postmortem
human brain tissues (1~3.5 hours) (Sethi et al., 2009). Together, these data suggest
that neuronal mechanisms regulating miRNA degradation are unique compared to
miRNAs found in peripheral tissues, where mature miRNA expression can be observed
for days following inhibition of miRNA transcription or processing in cardiomyocytes and
mouse embryonic fibroblasts (Van et al., 2007, Gantier et al., 2011). However, it
remains to seen whether rapid degradation is a general property of neuronal miRNAs,
or if these observed half-lives are a unique characteristic of a specific miRNA subset.
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TDMD (Target Directed MiRNA Degradation)
This unique regulation can be explained, in part, by the process of TDMD (target
directed miRNA degradation), which seems to be more efficacious in primary neurons
(De La Mata et al., 2015). TDMD is a phenomenon whereby a target RNA is capable of
inducing the degradation of its complementary miRNA counterpart, which then allows
the mRNA target to escape the canonical miRNA silencing pathway. Specifically,
extensive complementary binding at the 3’ region of the miRNA induces a
conformational change that releases the embedded 3’ end of the miRNA from AGO
(Pawlica et al., 2019, Sheu-Gruttadauria et al., 2019), which then exposes the 3’ end to
various enzymatic processes that ultimately lead to its degradation. Notably, the binding
requirements for TDMD are distinct from siRNA-mediated silencing which also requires
extensive 3’ complementarity. Specifically, structural modeling of the miRNA-target
duplex within AGO2 indicates that target pairing in the central regions beyond the 11th
nucleotide position is sterically inhibited. This contrasts starkly to the siRNA-mediated
silencing mechanisms which require complementarity at the central regions in addition
to the 3’ end, indicating that AGO2 adopts a structurally distinct conformation for TDMD
compared to siRNA-mediated slicing (Sheu-Gruttadauria et al., 2019). The minimal
architectural binding requirements of the miRNA:target to elicit TDMD are still the focus
of ongoing research. In Drosophila, a mismatch of up to 8 nucleotides at the 3’ end was
tolerated before TDMD impairment was observed (Ameres et al., 2010), whereas a 4
nucleotide central bulge flanked by extensive complementary binding was preferred to
elicit TDMD in mammalian neurons (De La Mata et al., 2015). The amount of
mismatched base pairs at the 3’ end that are tolerated to initiate TDMD likely varies
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between species and cell types; however, near perfect seed sequence complementarity
seems to be a requirement. Notably, artificial mRNA targets that lacked seed
complementarity were able to induce TDMD in vitro, (Park et al., 2017), but it remains to
be seen if such examples can arise in an endogenous cellular environment.
The basic principles of TDMD were initially discovered by the use of artificial mRNA
targets, such as antagomiRs and miRNA sponges. These synthetic targets were
designed with extensive complementarity and have been shown to accelerate the rate
of decay for their respective miRNAs in mammalian cells (Baccarini et al., 2011).
miRNA sponges are highly complementary RNAs transcribed from stably integrated
genetic components, and have been shown to elicit TDMD in multiple cell types. For
instance, these genetically engineered miRNA sponges effectively reduced endogenous
levels of miR-16 and miR-20 in 293T and HeLa cells (Ebert et al., 2007), as well as
miR-223 in hematopoietic stem cells (Gentner et al., 2008), although the efficacy of
TDMD was much more potent in neuronal cells compared to other cell types (De La
Mata et al., 2015, Kleaveland et al., 2018). Viruses have also evolved a cellular
mechanism reminiscent of TDMD to attack host defense systems, specifically through
their production of viral RNAs that can destabilize host miRNAs (Guo et al., 2014,
McCaskill et al., 2015). The Herpesvirus saimiri (HVS) virus, for example, expresses a
U-rich small non-coding RNA called HSUR1 that destabilizes the miR-27 family via
extensive base pairing at the 3’ end. Similarly, the murine cytomegalovirus (MCMV)
elicits the rapid TDMD of the miR-27 family through its own viral transcript—m169 (Libri
et al., 2012). The degradation of miR-27, which targets genes necessary to mount an
appropriate immune response, allows for the propagation of the viral genome.
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While TDMD had been successfully demonstrated using artificial or viral RNA
targets, it remained unclear whether this phenomenon could occur in normal physiology.
This was partly due to the apparent dearth of highly complementary miRNA targets
present in the mammalian genome. However, evidence for endogenous mRNA targets
capable of eliciting TDMD are starting to emerge, especially in the context of the central
nervous system (Bitetti et al., 2018, De La Mata et al., 2015, De La Mata et al., 2018,
Kleaveland et al., 2018, Wightman et al., 2018, Table 2). In the cerebellum of zebrafish,
libra—a long noncoding RNA—has been shown to destabilize miR-29b. Similarly, miR29b was targeted for degradation by nrep, a libra homolog, in the mouse cerebellum
(Bitetti et al., 2018). More recently, the Bartel lab demonstrated a complex network of
TDMD pathways in the mouse brain. Specifically, the long non-coding RNA Cyrano—a
key regulator in development—was found to trigger TDMD of the miR-7 family. The
reduction of miR-7 subsequently allowed for the accumulation of its downstream circular
RNA (circRNA) target, cdr1as. This target circRNA in turn, elicited a modest reduction of
miR-671, underscoring the interconnectivity of degradation pathways among varying
non-coding RNA species (Kleaveland et al., 2018). Taken together, these studies
provide evidence that TDMD occurs within neuronal systems, with evidence from both
endogenous and exogenous RNA targets. Furthermore, the efficacy of TDMD appears
to be higher in the central nervous system, as exogenous RNA targets elicited the
degradation of their respective miRNA to a greater degree in primary hippocampal
neurons and cerebellar granule cells compared to HEK293T and mouse embryonic
fibroblasts (De La Mata et al., 2015). However, it should be noted that this phenomenon
has also been reported to some degree in non-neuronal cells. In mouse fibroblasts,
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Ghini and colleagues identified hundreds of potential endogenous RNA targets capable
of eliciting TDMD. Among these, the endogenous mRNA Serpine1 was found to
destabilize miR-30b-5p and miR-30c-5p to regulate cell cycle re-entry processes (Ghini
et al., 2018). It remains to be seen if other endogenous targets will emerge in the
coming years, specifically in the central nervous system. Nevertheless, further
investigation is warranted to determine the extent to which TDMD can explain the rapid
miRNA degradation observed in neurons.
Table 2. RNA Targets that Elicit TDMD in the Central Nervous System
miR:TDMD
target

Species/ Tissue

Sequence Complementarity

References

miR-26b:
NREP

Zebrafish/
Cerebellum

UAGCACCAUUUGAAAUCAGUGUU
AUCGUGGUAAG_U__AGUCACAGA

(Bitetti et
al., 2018)

miR-7:
Cyrano

Mouse/Cerebellum,
Cortex

UGGAAGAC_UA_GUGAUUUUGUUGUU
ACCUUCUGUAACCACUAAAACAACAA

(Krol et al.,
2010)

miR-132:
Artificial
construct

Rat/ Primary
hippocampal
neurons

GCUGGUACCGACAUCUGACAAU
CGACCAUGGCNNN_GACUGUUA

(De La
Mata et al.,
2015)

miR-124:
Artificial
construct

Rat/ Primary
hippocampal
neurons

CCGUAAGUGGCGCACGGAAU
GGCAUUCANNN_GUGCCUUA

(De La
Mata et al.,
2015)

Potential Enzymes in the TDMD Pathway
The conformational changes induced by the miRNA:target interaction exposes
the miRNA to further enzymatic processing. Tailing, or non-templated addition, to the
miRNA 3’ end is performed by terminal nucleotidyl transferases (TNTases), and these
events have been shown to affect the stability of miRNAs (Table 3). For example,
TUT4—a terminal uridyl transferase—was found to oligouridylate pre-let-7 at the 3’ end.
This oligo(U) tail subsequently served as a signal for decay, catalyzed by the Perlman
syndrome exonuclease, DIS3L2 (Chang et al., 2013). In an alternative pathway,
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oligoadenylation at the 3’ end mediated by PAPD5 (non-canonical poly(A) RNA
polymerase) destabilized miR-21 via degradation by PARN (poly(A)-specific
ribonuclease), underscoring the potential diversity of miRNA degradation processes
(Boele et al., 2014). Furthermore, the length of the nucleotidyl additions was critical for
determining the stability of the miRNA. For instance, monoadenylation of mature miR122 catalyzed by GLD2, another poly(A) RNA polymerase, resulted in a stabilizing
phenotype; whereas, oligoadenylation of the same miRNA promoted its degradation
through PARN (D’Ambrogio et al., 2012, Katoh et al., 2015, Katoh et al., 2009). In
contrast, monoadenylation by GLD2 had no effect on the stability of miRNAs in the
hippocampus, indicating tissue specific regulation of miRNA degradation (Mansur et al.,
2016). Recently, RNA modifications, such as the 3’terminal 2’-O methylation, was also
shown to enhance the stability of miR-21-5p in non-small cell lung cancer (NSCLC)
(Liang et al., 2020).
Table 3. Tailing Enzymes Potentially Involved in the Regulation of TDMD in the
Brain
Enzyme

Function

Brain region
specificity

TUT1
(PAPD2)

Interacts with miR-27 isoforms upon
TDMD induction (Haas et al., 2016)

Expressed in
all regions

TUT2 (GLD2)

Monoadenylate miR-122,
Stabilizes miRNA (D’Ambrogio et
al., 2012, Kim et al., 2020)

Expressed in
all regions

TUT3
(PAPD5)

Oligoadenylate miR-21, Destabilizes
miRNA (Boele et al., 2014)

Expressed in
all regions

TUT4

Oligouridylate pre-let-7,
Signal for decay (Chang et al.,
2013)

Expressed in
all regions
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However, it remains unclear the extent to which these enzymatically edited
miRNA isoforms are functionally coupled to TDMD processes. For instance, only
DIS3L2 has been observed to degrade miRNAs after binding to a highly complementary
mRNA target (Haas et al., 2016). Additionally, after transfection with an artificial RNA
target, DIS3L2 was copurified with several components of both the TDMD and RNAinduced silencing complex: TUT1, XRN2, and AGO2 (Haas et al., 2016), underscoring
the close proximity of the tailing and degradation machinery. Furthermore, tailing
processes were initiated with the miRNA still bound to AGO2 (De La Mata et al., 2015,
Haas et al., 2016), implicating the critical role of target binding to the 3’ modification of
miRNA. In contrast, it appears that PARN-mediated miRNA degradation is independent
of TDMD, as degradation was observed to occur outside of RISC (Katoh et al., 2015).
However, the possibility remains that target binding is able to eject the miRNA from
RISC where it would be exposed to cytoplasmic exonucleases such as PARN and
XRN2. In fact, highly complementary targets have been shown to dissociate guide
RNAs from RISC in vitro (De et al., 2013). This pathway would reveal a novel and
understudied tailing-independent mechanism of TDMD.
Recent evidence, however, seems to indicate tailing mechanisms are, in large
part, independent of TDMD. For example, double knock out of both TUT4 and TUT7 did
not impair HSUR1 mediated TDMD of the miR-27 family (Sheu-Gruttadauria et al.,
2019). Likewise, the viral m169 transcript was able to invoke TDMD of the miR-27
family even after TUT1 knockdown (Haas et al., 2016). Finally, in the mouse brain,
GLD2 knockout had no effect on Cyrano-mediated TDMD of miR-7 (Kleaveland et al.,
2018), suggesting that while TDMD can expose the miRNA 3’ end to tailing
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modifications, this enzymatic event does not necessarily initiate miRNA degradation. It
is important to note, however, that there are 11 terminal nucleotidyl transferases
(TNTases) expressed in mammals with redundant functions (Warkocki et al., 2018);
therefore, it remains to be seen if the miRNA tailing mechanisms could be compensated
for by other TNTases in these knock out experiments.
Advantages of TDMD in Neurons
Further investigation is required to understand the molecular mechanisms of
TDMD, specifically in regard to its potency in the mammalian brain. The evidence
indicates that non-neuronal cells also possess the required molecular machinery for
TDMD processes, as transfection of artificial targets successfully elicits TDMD. For
instance, the Perlman syndrome exoribonuclease (DIS3L2), terminal uridylyl transferase
1 (TUT1), and 5’-3’ exoribonuclease 2 (XRN2) are all constitutively expressed with low
tissue specificity. Therefore, one possibility for the observed potency of TDMD in the
brain could be due to differential expression of endogenous targets. An exciting
possibility for endogenous TDMD targets in the brain could be circRNAs. These
circularized transcripts are non-coding RNAs that are formed from back-splicing events
and are highly expressed in the brain where, notably, approximately 20% of protein
coding genes were linked to circRNA formation (You et al., 2015). Furthermore,
circRNAs are relatively stable compared to other linear RNAs, as they are immune from
degradation through exoribonucleases.
Additionally, circRNAs have already been well characterized as miRNA sponges,
potentially having over 70 miRNA binding sites (Hansen et al., 2013). Therefore, it is not
difficult to envision that these highly expressed, yet stable, RNAs serve as endogenous
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targets for TDMD in the mammalian brain, as their stability could allow escape from
canonical miRNA-mediated silencing. Although circRNA mediated degradation of
miRNAs remains highly speculative, its functional role in the brain provides exciting
avenues for future research.
Nevertheless, the advantages of TDMD in neurons—especially at the synaptic
terminals—are abundantly clear. Neurons simultaneously integrate a variety of external
stimuli at the synapse, and recent evidence indicates that miRNAs along with the RISC
components are spatiotemporally localized to the synaptic terminals, primed to receive
external input (Hu et al., 2017). Indeed, miRNA abundance can be directly regulated by
synaptic activity, which in turn alters the landscape of local protein synthesis in
dendrites and axons (Hu et al., 2017). Therefore, the ability to rapidly adjust miRNA to
target mRNA stoichiometry is critical in the maintenance of normal neuronal function,
but it remains unknown if TDMD processes can be regulated by synaptic activity.
Interestingly, circRNAs have been shown to be enriched in the synapse as well (Sekar
et al., 2019), providing further evidence for its potential role as an endogenous neuronal
substrate for TDMD. The regulation afforded by TDMD would allow for the rapid finetuning of miRNA levels at the synapse, which has been shown to be critical for the
maintenance of neuronal homeostasis
MiRNA Function in the Brain and its Clinical Implications
Distinct miRNAs have been found uniquely in brain tissue. For example, miR-9
has been shown to be an important factor in neuronal differentiation (Smirnova et al.,
2005). Interestingly, miR-9 triggered the differentiation of embryonic stem cells as well
as neural stem cells into neurons (Saunders et al., 2010). miR-7, on the other hand,
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was found to be important for oligodendrocyte development and promoted myelination,
while miR-128 has been shown to be essential for synaptogenesis (Adlakha and Saini,
2014).
The dysregulation of miRNAs in the mammalian brain has been well
characterized in the pathogenesis of various neurodegenerative diseases (Sarkar et al.,
2019, Sharma et al., 2018, Table 4). While miRNA dysregulation is likely attributed to
deficits in various facets of multiple, interconnected molecular pathways, it can be
speculated that the dysregulation of miRNA degradation machinery is one mechanism
for miRNA overexpression in neuropathology. For instance, miRNA overexpression is
apparent in Alzheimer Disease (AD), where miR-125b upregulation enhanced tau
phosphorylation in primary neurons and in mouse brains, linking miR-125b to a
molecular feature of AD pathology (Cogswell et al., 2008, Lukiw et al., 2007). Similarly,
the upregulation of miR-146a led to an increase in the processing of amyloid precursor
protein (APP), which subsequently resulted in amyloid accumulation—both hallmarks of
AD (Sethi et al., 2009). Moreover, a group of miRNAs (miR-26b, miR-244, and miR106b), were upregulated in the substantia nigra and amygdala of patients with
Parkinson Disease (PD). Increased levels of these miRNAs inhibited genes in the
chaperone-mediated autophagy pathway, which ultimately impaired the sufficient
degradation of alpha synuclein protein, allowing for Lewy body deposit formation
(Alvarez-Erviti et al., 2013). The cause of the increased miRNA levels was not
determined in these cases; however, it is reasonable to predict that defects in mature
miRNA degradation might be a possible explanation. The dysregulation of miRNAs has
also been associated with other neurodegenerative diseases such as Huntington
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Disease (HD) and schizophrenia (23), underscoring the necessity of cellular
degradation processes to prevent overabundant miRNA expression in the brain.
Interestingly, a mutation in the DGCR8 enzyme was found to significantly increase the
risk for schizophrenia, suggesting that the
insufficient processing of pri-miRNAs was related to the diseased state (Stark et al.,
2008). Postmortem studies of brains from patients with schizophrenia revealed a
general decrease in miRNA expression, especially in the prefrontal cortex which is
critical for cognition and social behavior (Perkins et al., 2007). Therefore, further
investigation on the causal link between miRNA dysregulation and deficiencies in the
degradation machinery is critical to reveal novel molecular pathways contributing to
neurodegenerative disease.
Table 4. MiRNAs Associated with Neurodegenerative Disease
Pathology

Dysregulated miRNAs

Alzheimer Disease

miR-206, miR-219, miR-1323p, miR-212, miE-9, miR-125b,
miR-146a, miR-155, miR-34a,
miR-34c, let-7, miR-33, miR106b, miR-758

Parkinson Disease

miR-494, miR-7, miR-205, let7, miR-1, miR-29, miR-133b

Huntington Disease

miR-132, miR-9-5p, miR-9-3p,
miR-10b-5p, miR-34b

Schizophrenia

miR-9-5p, miR-29a-3p, miR106b-5p, miR-125a-3p, miR125b-3p
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Furthermore, as was previously mentioned, it is still unclear how miRNA
degradation itself is regulated. Specifically, hormonal triggers of miRNA degradation
have not been properly identified, especially in the context of the aging brain where
miRNA dysregulation is often observed (Sarkar et al., 2019). Therefore, it is crucial to
identify the neuronally enriched miRNAs that are also sensitive to circulating hormones,
as hormone levels fluctuate throughout the lifespan. Furthermore, these effects must be
determined within the context of aging as miRNA abundance has been shown to be
dependent on the cellular context. To that end, critical sequence determinants of
degradation within the mature miRNA must be elucidated, as these elements could
prove to be a focal point of regulation, specifically in their differential interactions with
RNA-binding proteins. Due to the immense regulatory potential of these neuronally
enriched miRNAs, the investigation of their degradation in the presence and absence of
circulating hormones has clear clinical implications during menopause and subsequent
hormone replacement therapy.

CHAPTER THREE
miR-9-5p AND -3p EXHIBIT RAPID, YET DISTINCT, DEGRADATION KINETICS IN
THE BRAIN
modified from “Kim, C. K., Asimes, A., Zhang, M., Son, B. T., Kirk, J. A., & Pak, T. R.
(2020). Differential Stability of miR-9-5p and miR-9-3p in the Brain Is Determined by
Their Unique Cis- and Trans-Acting Elements. eNeuro, 7(3), ENEURO.0094-20.2020.”

Introduction
Posttranscriptional regulation of protein-coding genes (mRNA) is a critical
mechanism for maintaining cellular homeostasis. Cells must orchestrate a delicate
balance between the synthesis of new molecules and the degradation and/or export of
older ones. microRNAs (miRs) are a major contributor to this process, as it is estimated
that they regulate over 60% of all protein-coding genes in eukaryotic cells (Friedman et
al., 2009). The major steps for the biogenesis of miRs have largely been determined;
however, the mechanisms of miR degradation are still the focus of ongoing research.
Earlier reports suggested that miRs are globally more stable compared to mRNA
(Gantier et al., 2011; Rüegger and Großhans, 2012; Zhang et al., 2012;), and this
stability is thought to be imparted by miR association with RNA binding proteins, such
as Argonaute 2 (AGO2). When bound to AGO2, structural analyses dictate that the 5’
and 3’ ends of the mature miR are embedded within the protein, thereby shielding it
from potential exoribonucleases (Wang et al, 2008). Recently, mechanisms of TDMD
(target-directed miR degradation) have been discovered whereby a highly
complementary, endogenous RNA target is capable of dislodging the 3’ end of the
36
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miR from the AGO2 PAZ domain, allowing it to be more accessible to trans factors
responsible for RNA tailing, trimming, and ultimately degradation (Park et al., 2017;
Bitetti et al., 2018; Ghini et al., 2018; Kato, 2018; Wightman et al., 2018). The reported
mechanisms of TDMD suggest that cis sequence motifs of the miRs, as well as the
recruitment of trans acting proteins to the site of degradation, are crucial determinants
of miR degradation kinetics; however, the specifics of these factors remain elusive.
To further add to the complexity of miR degradation, miRs exhibit varying halflives between different tissues and cell types within an organism (Li et al., 2013). For
example, miR stability in the central nervous system is a striking exception to the long
half-lives generally observed in peripheral organs. Neuronal miRs are highly unstable
and can be regulated by neuronal activity, suggesting that their silencing function is
temporally controlled by external stimuli (Krol et al., 2010; Fu et al., 2016). Indeed, a
variety of chemical and electrical stimuli has been shown to dramatically alter miR
expression levels in cultured neurons (for review Sim et al., 2014), adding another layer
of regulation to the unstable nature of neuronal miRs. Notably, the half-life of one of the
most abundant neuron-enriched miRs, miR-9-5p, was reported to be less than one hour
in primary neocortical cells (Sethi et al., 2009). However, the degradation kinetics of its
duplex counterpart, miR-9-3p, was not considered in this study. miR-9-5p is designated
as the “guide” strand in most deuterostomes, and its annotation is derived from the
mature miR sequence being embedded in the 5’ stem of the miR-9 precursor;
conversely, miR-9-3p, or the “passenger” strand, is embedded in the 3’ stem. For most
miRs, it is generally accepted that the guide strand of the duplex is preferentially loaded
onto AGO2 and is the functionally relevant strand, while the passenger strand is quickly
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degraded. However, both miR-9-5p and miR-9-3p are neuron-enriched, and their
individual functional contributions have been extensively described in regulating critical
neuronal processes such as driving neuronal differentiation, initiating angiogenesis, and
modulating synaptic plasticity (Yuva-Aydemir et al., 2011; Coolen et al., 2013; Sun et
al., 2013; Giusti et al., 2014; Richner et al., 2015; Sim et al., 2016; Madelaine et al.,
2017). The significance of their individual functions implies that both the -5p and -3p
transcripts must be relatively stable and separately loaded onto AGO2; however, the
degradation kinetics of these two miRs, especially miR-9-3p, are not well characterized
in the literature. Therefore, the studies herein focused on discerning the relative
degradation kinetics of miR-9-5p and miR-9-3p due to their neuronal enrichment and
their significant roles in regulating neuronal physiology.
The objective of this study was to determine the relative degradation kinetics and
the factors that govern miR-9-5p and miR-9-3p degradation specifically in the rat
hypothalamus and ventral hippocampus: regions of the brain that regulate homeostasis
in a variety of physiological processes. Moreover, previous studies showed that miR-95p and miR-9-3p expression increased with advanced age in these brain regions (Rao
et al., 2013). Therefore, in this study, we investigated miR-9 degradation kinetics in
aged rats (18-months) when expression levels were highest, underscoring the
possibility that the kinetics of miR turnover would be functionally relevant. We
hypothesized that the degradation kinetics of miR-9-5p in the aged hypothalamus would
be distinct from that of miR-9-3p. Moreover, we predicted that any differences in miR
degradation kinetics would be due to intrinsic differences in nucleotide composition (i.e.
cis factors) or through differential recruitment of trans factors that contribute to
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degradation processes. These possibilities were tested in vivo using a rat model and in
vitro using hypothalamic-derived neuronal cells lines. Collectively, our results indicate
that miR-9-5p stability is distinct from that of miR-9-3p, and this difference can be
explained, in part, by their unique cis and trans elements.
Results
MiR-9-3p was More Stable than MiR-9-5p in a Hypothalamic Cell Line
We used a basic biochemical approach to determine if the unique nucleotide
sequence of miR-9-5p and miR-9-3p affected their degradation kinetics when exposed
to identical cellular lysate components. Importantly, to our knowledge, this assay has
only been done previously in cell-free conditions making this the first study to observe
the degradation products of these miRs following exposure to native cell and whole
tissue constituents. First, 32P-labeled oligonucleotides identical to each miR were
incubated in cell lysate purified from hypothalamic-derived neuronal cells (IVB). The
cells were subjected to a mild lysis buffer that was not likely to disrupt the nuclear
envelope, as we hypothesized that most miR degradation factors would reside in the
cytoplasm. Each construct was first visualized at the correct size compared to a nucleic
acid ladder size marker (Fig. 2A). Next, radiolabeled miR-9-5p and miR-9-3p were
incubated in IVB lysate for 5 different time points (T0, 15, 60, 120, 240 min.). Our results
showed that miR-9-3p, canonically considered the passenger strand, was more stable
than miR-9-5p (Fig. 2B, C). Roughly ~50% of the full length miR-9-5p signal was
reduced at the 15-minute time point, and by the 1-hour time point, the full-length signal
was completely abolished. Comparatively, the signal corresponding to full length miR-93p was significantly higher than miR-9-5p at the 1-hour time point, indicating slower
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degradation kinetics (p = 0.048, Fig. 2B, D). A comparison of the mean half-lives
derived from the best-fit exponential decay functions indicated that miR-9-3p was
approximately twice as stable as miR-9-5p, exhibiting half-lives of 31.85 and 13.09 min.,
respectively (Fig. 2C, E). Importantly, a small fraction of both radiolabeled constructs
(miR-9-5p and miR-9-3p) were shown to bind AGO2, but not AGO4 or β-actin,
demonstrating that the radiolabeled miRs bind specifically to relevant RNA binding
proteins in this assay (Fig. 3).
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Figure 2. MiR-9-3p was More Stable than MiR-9-5p in a Hypothalamic Cell Line. A)
Gel electrophoresis of 32P-labeled miR-9-5p and miR-9-3p showing bands at their correct
size: 23 and 22 nucleotides (nT), respectively. B) Representative gel image of miR-9-5p
and miR-9-3p degradation over time (min.) following incubation in hypothalamic-derived
neuronal cell (IVB) lysate for 0, 15, 60, 120, or 240 min. C) Scatterplot of normalized
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densitometry values analyzed from gel images and fit with an exponential decay
function (black line = miR-9-5p; red line = miR-9-3p; N = 4/group). D) Normalized
densitometry values at the 60 min. time point for miR-9-5p and miR-9-3p. Data are
represented as mean ± SEM (N = 4/group). E) Mean half-lives of miR-9-5p and miR-93p derived from best-fit exponential decay functions. Results are represented as mean
± SEM (N = 4/group), and horizontal line overlaying the bar graph indicates the median.
Data were analyzed using a two-sample t-test.

Figure 3. AGO2 Binds to 32P-Labeled MiR-9-5p and MiR-9-3p. Representative gel
image of 32P-labeled miR-9-5p, miR-9-3p, and an equimolar equivalent mixture of both
following immunoprecipitation with A) AGO2, B) IgG control, and C) AGO4 and β-actin.

We also observed size differences in the miR-9-5p and miR-9-3p degradation
products (i.e. smaller size bands on the gel), suggesting that the miRs were cleaved at
different locations. Specifically, miR-9-5p had 4 discrete bands corresponding to the
degradation products, whereas miR-9-3p only had 2 discrete bands (Fig. 2B). Next, we
used a second method to verify that miR-9-3p was more stable by measuring the
degradation rates of endogenously expressed mature miR-9-5p and miR-9-3p following
transcriptional inhibition with actinomycin D. Consistent with the miR degradation
assays, these experiments also showed that miR-9-3p was more stable than its miR-95p counterpart (Fig. 4). Two-way ANOVA analysis revealed that there was a significant
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main effect of miR construct. Subsequent post hoc analyses using Tukey’s HSD
revealed that at the 1-hour time point, miR-9-3p levels were significantly higher (p =
0.049) compared to miR-9-5p, indicating a more stable profile (Fig. 4). Notably, this
assay used intact live cells and confirmed that the relative stability of miR-9-3p
compared to miR-9-5p was similar to the purely biochemical approach of the miR
degradation assay described above.

Figure 4. MiR-9-3p was More Stable than MiR-9-5p Following Transcriptional
Inhibition. Hypothalamic-derived IVB cells were treated with the transcriptional inhibitor
actinomycin D for 2 hours. Cells were lysed at 0, 15, and 60 minutes following
treatment, total RNA was isolated, and RT-qPCR was performed for miR-9-5p and miR9-3p (N = 5/group). Results were analyzed using the ΔΔCt method and are represented
as mean fold change ± SEM, and horizontal line overlaying the bar graph indicates the
median. Data were analyzed by two-way ANOVA with time and miR construct as
factors. A Tukey’s post hoc test was performed to determine statistically significant
differences between group means.
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MiR-9-3p was More Stable than MiR-9-5p in a Brain Region Dependent Manner
Next, the degradation kinetics of miR-9-5p and miR-9-3p were investigated using
brain tissue lysate from 3 different rat brain regions: the preoptic area (POA), the ventral
hippocampus (vHIPP), and the supraoptic nucleus (SON). These regions were selected
due to previous reports demonstrating endogenous miR-9-5p and miR-9-3p expression
in these regions (Rao et al., 2013; 2015). Unexpectedly, the time course for both miR-95p and miR-9-3p degradation in each of these brain regions was consistently faster than
what was observed in the hypothalamic IVB neuronal cell lines, even though total
protein concentrations were identical in the different lysates (Fig. 5A, B). The signal
corresponding to the full length miR-9-5p disappeared almost immediately upon
exposure to brain tissue lysate; therefore, T0 had to be redefined using lysis buffer
alone to determine the correct starting concentration, and the time scales were adjusted
accordingly to T0, 1, 15, 60, and 120 min. (Fig. 5A). Our results also showed brain
region specific differences in miR-9-5p degradation. For instance, the signal
corresponding to full length miR-9-5p was present at the 1-minute time point in POA
lysate, but absent in vHipp and SON lysate (Fig. 5A). A two factor ANOVA analysis of
miR half-lives showed that there was a statistically significant main effect of brain region
(factor 1) and a significant main effect of miR construct (factor 2).
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Figure 5. MiR-9-3p was More Stable than MiR-9-5p in a Brain Region Dependent
Manner. A) Representative gel image of 32P-labeled miR-9-5p and miR-9-3p following
incubation with rat brain lysate (N = 3/brain region). POA-preoptic area, vHIPP-ventral
hippocampus, SON-supraoptic nucleus B) Scatterplot of normalized densitometry
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values analyzed from gel images and fit with an exponential decay function showing
brain region specific degradation kinetics of miR-9-5p and miR-9-3p. C) Mean half-lives
of miR-9-5p and miR-9-3p in various brain regions derived from best-fit exponential
decay functions. Results are represented as mean ± SEM (N = 3/group), and horizontal
line overlaying the bar graph indicates the median. Data were analyzed by two-way
ANOVA with brain region and miR construct as factors.
A Tukey’s post hoc test was performed to determine statistically significant
differences between group means. There was also a statistically significant interaction
between brain region and miR construct, demonstrating that the degradation rate of
each miR was dependent on brain region. Consistent with the data observed in the IVB
cell line, the half-life of miR-9-3p was significantly longer in all three brain regions
compared to miR-9-5p (Fig. 5C). Full length miR-9-3p persisted to the 15-minute time
point in every brain region. However, differential degradation kinetics for miR-9-3p were
still observed dependent on brain region, as miR-9-3p exhibited a longer half-life in the
SON and POA compared to the vHipp (Fig. 5C). These data suggest that miR
degradation might occur rapidly in the intact rat brain, but there are also distinct regiondependent kinetics.
Rapid MiR-9-5p Degradation In Vivo was Dependent on Protein Concentration of
the Lysate
The rapid degradation of miR-9-5p and miR-9-3p that was observed in the brain
tissue lysate suggested that there could be enriched levels of specific miR degradation
factors compared to the cell lysate. Therefore, to determine whether rapid degradation
of miR-9-5p adhered to first order degradation kinetics, radiolabeled miR-9-5p was
incubated in various dilutions of SON lysate (1:10, 1:100, 1:1000) for the miR
degradation assay. The SON was utilized for these experiments, because this was the
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region where miR-9-5p exhibited the fastest degradation (Fig. 5B). The results showed
a steady increase in miR-9-5p stabilization upon increased lysate dilution, culminating in
the complete elimination of any degradation products after 4 hours of incubation at a
dilution of 1:1000 (Fig. 6A, B). We also hypothesized that the unknown miR degradation
factors present in the brain tissue lysate were proteins, and not nucleic acids, steroids,
or other chemical compounds. To test this hypothesis, we performed the same assays
using lysis buffer alone (i.e. no lysate present) and compared that to proteinase-K
treated SON lysate (Fig. 6A). Our results demonstrated that miR-9-5p was stable across
all time points in both of these treatment groups, suggesting that an unknown protein of
fairly high abundance was present in the brain tissue lysate and likely contributed to
rapid miR-9-5p degradation.
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Figure 6. Rapid MiR-9-5p Degradation in Rat Brain (SON) Tissue Lysate was
Dependent on Protein Concentration of the Lysate. A) Representative gel image of
32Plabeled miR-9-5p following incubation with 1:10, 1:100, and 1:1000 dilutions of rat
brain (SON) lysate, lysis buffer alone, or following SON lysate treatment with proteinase
K for 60 min. at 60°C. B) Scatterplot of normalized densitometry values analyzed from
gel images and fit with an exponential decay function showing concentration dependent
degradation kinetics of miR-9-5p (N = 4/group).

Degradation of MiR-9-5p was Slower in Primary Astrocytes Compared to Whole
Brain Tissue Lysate.
Brain tissue lysate is a heterogeneous cell population consisting primarily of
neurons and various types of glial cells. We predicted that the glial contribution might
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account for the enhanced rate of degradation observed in brain tissue lysate compared
to the slower rate observed in the homogenous neuronal cell lysate (i.e. IVB cells).
Therefore, we used primary astrocytes isolated from the rat brain to determine the
contribution of glial cells to miR-9-5p degradation. Contrary to our prediction, miR-9-5p
degradation kinetics were relatively stable when incubated with astrocyte only lysate.
Specifically, the full length miR-9-5p signal could be detected at the 15-minute time
point (Fig. 7A, B), suggesting that there are inherent differences in miR degradation
kinetics between immortalized neuronal cell lines and neurons from the rat brain.
Further, the average half-life was 17.84 min. closely resembling the profile we observed
with the neuronal cell lysate (IVB cells) (Fig. 7C).
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Figure 7. Degradation of MiR-9-5p was Slower in Primary Astrocytes Compared to
Rat Brain (SON) Tissue Lysate. A) Representative gel image of 32P-labeled miR-9-5p
following incubation with rat brain tissue (SON) lysate or rat primary astrocytes for 0, 1,
15, 60, or 120 min (N = 3). B) Scatterplot of normalized densitometry values analyzed
from gel images and fit with an exponential decay function. C) Mean half-lives of miR-95p were derived from best-fit exponential decay functions. Results are represented as
mean ± SEM (N = 3/group), and horizontal line overlaying the bar graph indicates the
median. Data were analyzed using a two-sample T-test.
Nucleotide Sequences at Both the 5’ and 3’ End Contribute to MiR-9 Stability
One possible explanation for the observed degradation differences in miR-9-5p
and miR-9-3p was the distinct nucleotide sequences (i.e. cis factors) of each miR,
especially considering that differences in degradation rates and cleavage products
occurred despite both miRs being exposed to identical lysate conditions. Moreover, the
presence of multiple degradation products for miR-9-5p and miR-9-3p suggested that at
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least some of the degradation occurred in a 3’ to 5’ direction, due to the radiolabeled
phosphate being located at the 5’ position and subsequent visibility of a smaller
radiolabeled products on the gel. Therefore, to test the importance of the 3’ end
nucleotide sequence in determining stability, the last 3 nucleotides of miR-9-5p and
miR-9-3p were exchanged to create two new chimeras: 5p* and 3p*. The 5p* chimera
had a UGA to AGU substitution at the 3’ end, while the 3p* had an AGU to UGA
substitution (Fig. 8A). Our results demonstrated that swapping just 3 nucleotides at the
3’end of miR-9-5p with miR-9-3p (i.e. the *5p construct) was sufficient to significantly
increase the stability of miR-9-5p at 1.0 min. when incubated with lysate taken from the
SON (p = 0.004; Fig. 8B, D). Conversely, this swap had the opposite effect on miR-9-3p
(i.e. the 3p* construct) with it showing significantly faster degradation at 15 min.
compared to its native sequence (p = 0.045; Fig. 8B, E). Therefore, swapping the 3’ end
nucleotides caused miR-9-5p to degrade at a more similar rate as miR-9-3p and viceversa, suggesting that this sequence motif directly contributed to miR degradation
kinetics (Fig. 8D, E).
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Figure 8. Nucleotide Sequences at Both the 5’ and 3’ End Contribute to MiR-9
Stability. A) Schematic diagram showing the nucleotide compositions of the miR-9
constructs: 5P = full-length canonical miR-9-5p, 3P = full-length canonical miR-9-3p,
5P* = miR-9-5p with a UGA to AGU substitution at the 3’ end, 3P* = miR-9-3p with an
AGU to UGA substitution at the 3’ end, 5p isomiR = miR-9-5p with a U deletion at the 5’
end. Red font indicates nucleotide variation from canonical sequences. B)
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Representative gel image showing the degradation kinetics of 32P-labeled miR-9-5p, -3p,
5p*, 3p*, and 5p isomiR following incubation in rat brain (SON) lysate for 0, 1, 15, 60, or
120 min. C) Scatterplot of normalized densitometry values analyzed from gel images
and fit with an exponential decay function showing that both 5’ and 3’ end modifications
affect stability (N = 3-4/group). D) Normalized densitometry values at the 1 min. time
point for the miR-9-5p, 5p*, and isomiR constructs. Results are represented as mean ±
SEM (N = 3-4/group). Data were analyzed by one-way ANOVA with miR construct as
the categorical factor. A Tukey’s post hoc test was performed to determine statistically
significant differences between group means. E) Normalized densitometry values at the
15 min. time point for miR-9-3p and -3p*. Results are represented as mean ± SEM (N =
3-4/group), and horizontal line overlaying the bar graph indicates the median. Data were
analyzed using a two-sample t-test.
It was evident that some amount of degradation also occurred from the 5’ end,
based on a small decrease in the relative intensity of the gel bands from the initial
incubation time point to the final time point. Therefore, we altered miR-9-5p to match
that of a documented endogenous isomiR to determine the contribution of 5’ nucleotides
to the degradation profile. This isomiR is endogenously generated from alternative
Drosha cleavage and results in one less uracil at the 5’ terminal end of the miR (BofillDe Ros et al., 2019). Interestingly, the miR-9-5p isomiR tended to be more stable than
the miR-9-5p annotated as the wildtype (p = .065; Fig. 8B, D). Together, these data
provide evidence that cis elements at both the 5’ and 3’ ends of the miR are critical for
determining its degradation kinetics.
Since an intermediary degradation phenotype was observed by only swapping 3
nucleotides at the 3’ end of the miRNA, we wanted to determine the minimal number of
nucleotides to completely reverse the kinetics of each miRNA to the counterpart.
Therefore, additional chimeras were designed to substitute the last 6 and 9 nucleotides
of miR-9-5p and miR-9-3p (Fig. 9A). Unexpectedly, increasing the number of swapped
nucleotides for miR-9-5p actually destabilized it back to the wildtype (Fig. 9B).
Conversely, the 3p9, which contained 9 end nucleotides of miR-9-5p, completely
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destabilized the miRNA, resembling the kinetics of wildtype miR-9-5p (Fig.9C).
However, 3p6, which contained 6 end nucleotides of miR-9-5p, was just as stable as
wild type miR-9-3p at the 1-minute time point (Fig. 9C), suggesting that it’s not just the
3’ end that determines the rate of degradation. Rather, there is likely some cooperation
between the 3’, 5’, and seed regions to determine the stability of a miRNA.
5P: UCUUUGGUUAUCUAGCUGUAUGA
3P: AUAAAGCUAGAUAACCGAAAGU
5P6: UCUUUGGUUAUCUAGCUGAAAGU
3P6: AUAAAGCUAGAUAACCGUAUGA
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Figure 9. 3’ Sequence Elements can Determine the Rate of Degradation for MiR-93p. A) Schematic diagram showing the nucleotide compositions of the miR-9
constructs: 5P = full-length canonical miR-9-5p, 3P = full-length canonical miR-9-3p,
5P6 = miR-9-5p with a GAAAGU substitution at the 3’ end, 3P6 = miR-9-3p with an
GUAUGA substitution at the 3’ end, 5p9 = full-length canonical miR-9-5p with a
ACCGAAGU substitution, and 3p9 = full-length canonical miR-9-3p with a
GCUGUAUGA substitution. Red font indicates nucleotide variation from canonical
sequences, and blue font indicates seed sequence. B) Normalized densitometry values
at the 1 min. time point for the miR-9-5p, 5p3, 5p6, and 5p9. Results are represented as
mean ± SEM (N = 3-4/group). C) Normalized densitometry values at the 1 min. time
point for the miR-9-3p, 3p3, 3p6, and 3p9. Results are represented as mean ± SEM (N
= 3-4/group). Data were analyzed by one-way ANOVA with miR construct as the
categorical factor. A Tukey’s post hoc test was performed to determine statistically
significant differences between group means
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MiR-9-5p and MiR-9-3p were Associated with Distinct Proteins in the Ventral
Hippocampus
The contribution of unique cis elements to miR degradation rates suggested that
these specific nucleotide sequences might recruit different trans factors, which then
resulted in distinct degradation products for miR-9-5p and miR-9-3p. Our data also
demonstrated that miR degradation was dependent on unknown proteins present in the
brain tissue lysate (Fig. 6B). Therefore, we analyzed the proteins associated with each
miR using a discovery-based mass spectrometry approach to determine if these miRs
were associated with distinct proteins that might be involved in RNA degradation
processes. The ventral hippocampus was used for the proteomic studies as it
represented a relatively large region of the brain compared to smaller specific
hypothalamic nuclei, allowing for a sufficient starting concentration of protein.
Biotinylated miR-9-5p and miR-9-3p (Fig. 10A) were incubated with vHipp lysate, and
bound proteins were eluted and run on a 10% SDS PAGE gel. We focused on
identifying proteins from prominent bands present at the 45 ~ 55 kDa range that was
evident upon electrophoresis of proteins following streptavidin-bead purification (Fig.
10B). These bands were subsequently digested into smaller peptide fragments and
analyzed by mass spectrometry.

56

Figure 10. MiR-9-5p and MiR-9-3p were Associated with Distinct Proteins in the
Ventral Hippocampus. A) Various length nucleotides matching the sequence for miR9-5p (23, 16, 12 nT) and miR-9-3p (22, 16, 12 nT) were modified with a biotin tag on the
5’ end and incubated with lysate from the rat ventral hippocampus (vHIPP). B)
Biotinylated miR constructs were purified using streptavidin-coated magnetic beads and
resolved on a 10% SDS PAGE gel followed by Coomassie G-250 staining. Red box
indicates gel bands that were dissected for in-gel digestion followed by mass
spectrometry. C) Venn diagrams with number of unique proteins identified by mass
spectrometry compared between miR-9-5p and miR-9-3p at various sequence lengths
plus beads only, or D) comparison of identified proteins within miR-9-5p (23, 16, 12 nT)
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and miR-9-3p (22, 16, 12 nT). Red color numbers indicate proteins unique to each
construct and black numbers indicate proteins common between constructs. Blue
lettering indicates known RNA binding proteins.

We also analyzed the proteins that were associated with the approximated
degradation products of miR-9-5p and miR-9-3p in the vHipp by creating biotinylated
sequences that were shorter in length from the 3’ direction (16 and 12 nucleotides each)
(Fig. 10A). These shortened constructs were selected due to the relative stability of the
degradation products compared to the full-length transcript. Interestingly, the proteins
associated with these shortened constructs were also enriched at the 45 ~ 55 kDa
molecular weight range (Fig. 10B). Mass spectrometry analysis revealed full-length
miR-9-5p had 9 unique associated proteins compared to 7 unique proteins for miR-9-3p
(Fig. 10C, Table 5). The shortened miRs also had distinct proteins associated with
them, not only between the -5p and -3p transcripts, but also compared to their own
respective full-length transcripts (Fig. 10C, D; Table 5). We used Panther gene ontology
software to analyze the identified proteins according to their function, and the most
represented functional class for full-length miR-9-5p was related to cellular metabolism
(~33%, Table 6). In contrast, the most represented functional class of proteins captured
by full-length miR-9-3p was related to cytoskeletal organization and transport (~57%,
Table 6). Moreover, approximately 44% of the 9 unique proteins identified for miR-9-5p
were previously reported to have RNA binding capabilities.
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Table 5. List of Unique Proteins that were Associated with Various Length
Nucleotides Matching the Sequence for MiR-9-5p (23, 16, 12 nT) and MiR-9-3p (22,
16, 12 nT), as Identified by Mass Spectrometry Using PEAKS™ Software.
5P 23 nT
Protein
D-3-phosphoglycerate
dehydrogenase
Glucose-6-phosphate 1dehydrogenase
Heterogeneous nuclear
ribonucleoprotein
60 kDa heat shock protein
Eukaryotic translation initiation factor
5
Cytoplasmic dynein 1 light
intermediate chain 2
Tubulin alpha-1C chain
Dihydrolipoyl dehydrogenase
Pleiotropic regulator 1

3P 22 nT
Protein
Peripherin
Excitatory amino acid transporter 1
Microtubule-associated protein 1A
Tubulin alpha-1A chain
Caveolae-associated protein 1
Vesicular glutamate transporter 1
26S proteasome regulatory subunit
6A

5P 16 nT
Protein
Glyceraldehyde-3-phosphate
dehydrogenase
Aspartate--tRNA ligase cytoplasmic
Mitochondrial-processing peptidase
subunit alpha
Kazrin
Cytoplasmic dynein 1 light
intermediate chain 2
26S proteasome regulatory subunit
6A
Phosphatidylinositol 5-phosphate 4kinase type-2 alpha
Aldehyde dehydrogenase X

3P 16 nT
Protein
Caveolae-associated protein 1
Keratin type II cytoskeletal 6A
Plasminogen activator inhibitor 1
RNA-binding protein
Sorting and assembly machinery
component 50 homolog
Keratin type II cytoskeletal 2
epidermal
Histone-binding protein RBBP7

5P 12 nT
Protein
S-adenosylhomocysteine
hydrolase-like protein 1
Pre-mRNA-processing factor 19
Keratin type II cytoskeletal 73
Actin gamma-enteric smooth
muscle

3P 12 nT
Protein
Excitatory amino acid transporter
1
Pleiotropic regulator 1
Microtubule-associated protein 1A
26S proteasome regulatory
subunit 6A
Myelin proteolipid protein
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Table 6. Table Summarizing Proteins Identified by Mass Spectrometry that were
Associated with Various Length Nucleotides Matching the Sequence for MiR-9-5p
(23, 16, 12 nT) and MiR-9-3p (22, 16, 12 nT) and Organized by Functional Class
According to Panther Gene Ontology Analysis.
Cytoskeletal

Membrane
trafficking

Protein
modifying

Transporter

Metabolism

miR-9-5p

22.2%

—

—

—

33.3%

11.1%

11.1%

16 nT

12.5%

—

25%

—

37.5%

—

12.5%

12 nT

40%

—

—

—

20%

—

—

28.6%

14.3%

14.3%

28.6%

—

—

—

16 nT

—

16.7%

—

—

—

16.7%

—

12 nT

20%

—

20%

20%

—

—

—

miR-9-3p

Nucleic
acid
binding

Translation

Overall, the total number of identified proteins was reduced for each miR as its
sequence was progressively shortened. However, the representation of metabolismrelated proteins remained high in the proteins associated with both the full-length and
the 16 nT miR-9-5p fragment (Fig. 10D; Table 6). Similarly, both the full-length miR-9-3p
and its 16 nT fragment was associated with CAVIN1 (caveolae associated protein 1), a
protein implicated in ribosomal RNA synthesis, but this association was lost at the 12 nT
length (Fig. 10D). The proteins associated with the 12 nT fragment (miR-9-3p) also did
not have a dominant functional class, but PLRG1 (pleiotropic regulator 1), a
spliceosomal component, was identified as a potential binding partner. The proteins
associated with the 12 nT (miR-9-5p) fragment were again most represented in protein
classifications pertaining to metabolism and cytoskeletal organization (~60%),
suggesting that miR-9-5p retains proximity to proteins in the same functional milieu
despite its degradation (Fig. 10D; Table 6). Overall, these data identified potential
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interactions between the miR-9-5p and -3p degradome and other RNA processes such
as splicing, mRNA processing, and ribosomal RNA synthesis in the rat hippocampus.
Discussion
The determinants of miR degradation kinetics in the context of the central
nervous system are poorly understood. In the present study, we describe the novel
finding that miR-9-3p was more stable than its duplex counterpart, miR-9-5p, when
exposed to identical neuronal cell lysates. Our current view of miRs dictates that the
mature strand designated as the “guide”, often derived from the 5’ stem of the pre-miR,
is more stable than the strand designated as the “passenger”, making these data a
novel and likely biologically relevant finding. Moreover, our data demonstrated that the
relative stability of each strand was dependent on their unique cis factor sequence
motifs residing at the 3’ end, perhaps through recruitment of distinct degradation factors
that are unique to each miR. Indeed, we identified potential trans acting factors that
were differentially associated with not only full length miR-9-5p and miR-9-3p, but also
to their approximated degradation products. We also showed that the relative
abundance of the protein factors contributing to the differential degradation rates of
miR-9-5p and miR-9-3p was likely different depending on brain region. Taken together,
these data contribute to the current understanding of miR degradation kinetics,
specifically in the biologically relevant context of the female rat brain.
Our data are consistent with previous studies suggesting that miRs in the brain
are degraded rapidly, underscoring the importance of understanding how these
relatively unstable miRs are able to exert functional effects downstream. miR-9-5p and
miR-9-3p have repeatedly been shown to be neuron-enriched, and previous studies
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have demonstrated a negative correlation between miR stability and overall expression
(Li et al., 2013). Neuronal miR-9-5p and miR-9-3p seem to follow this pattern: they are
both highly expressed and rapidly degraded (Sethi et al., 2009; Amar et al., 2012),
supporting a model whereby there is constitutive production and turnover of these
particular transcripts. A potential benefit of such steady state kinetics is readily apparent
in the context of neuronal systems in which the cell could quickly respond to dynamic
changes in extracellular input, such as changes to synaptic firing frequency. Indeed, an
example of activity-induced changes to miR stability was observed in retinal neurons
responding to changes to light/dark stimuli (Krol et al., 2010). The relative stability of
miR-9-3p that was observed from our data, (Fig. 2D, Fig. 5C) suggests that the -3p
strand could have a more prominent role in regulating neuronal function compared to its
-5p counterpart, making the ‘guide’ and ‘passenger’ designation somewhat arbitrary in
neuronal physiology. This assertion is supported in a previous report demonstrating that
miR-9-3p, but not -5p, was involved in the regulation of hippocampal memory and
synaptic plasticity (Sim et al., 2016).
Another novel finding of this study was the identification of distinct protein binding
partners for miR-9-5p and miR-9-3p (Fig. 10C), and to our knowledge this study is the
first to identify proteins associated with these mature miRs and their shorter degradation
products. Eukaryotic translation initiator 5 (EIF5) was one identified protein that was
associated with the full length miR-9-5p, but not miR-9-3p, in the vHIPP (Fig. 10C). EIF5
has been shown to interact with EIF1A via its C-terminal domain (Luna et al., 2013), and
EIF1A is a recently discovered component of the RNA-induced silencing complex
(RISC) (Yi et al., 2015). These data raise the possibility that an EIF1A:EIF5 complex
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could be associated directly, or indirectly, with miRs that are loaded onto RISC. Another
interesting protein that was identified in the vHipp was tRNA ligase, as it was shown to
only associate with the approximated miR-9-5p degradation product (16nt) (Fig. 10D).
Recently, tRNA fragments have been shown to be loaded onto AGO and even exert
gene regulatory functions (Kuscu et al., 2018), suggesting potential crosstalk between
the molecular pathways of tRNA and miR degradation products.
The importance of the proteins that we found associated with the shorter miR
fragments (i.e. the approximated degradation products) is unclear. The proteins
appeared to be specific to each size product (16 vs. 12 nT), and the total number of
associated proteins were reduced as the nucleotide sequence was progressively
shortened (Fig. 10C-E). Direct and specific protein binding would suggest that these
miRs could be functional and potentially bind to the same targets as the full-length
parent, given that the entire 8 nT seed sequence remained intact. There is no evidence
that these short fragments can bind to AGO proteins making it unlikely that any
functional effect would be similar to the full-length miR; however, these highly stable
short fragments could block the ability of a full-length miR to bind to its mRNA target
through competition at the seed sequence. The shorter degradation products were
much more stable than the full length miRs, and one possibility is that the associated
proteins are important for maintaining the stable expression of these fragments.
However, it is important to consider that due to the crosslinking reaction required for
immunoprecipitation, the identified proteins represent only those that were in close
proximity with the biotinylated miR of interest and do not necessarily reflect direct
binding.
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The myriad of molecular factors contributing to the rapid degradation of miRs in
neurons have still not been fully elucidated. One possibility is that neuronal miRs are
partially regulated by the process of target-directed miR degradation (TDMD) (Park et
al., 2017; Bitetti et al., 2018; Ghini et al., 2018; Kato, 2018; Wightman et al., 2018).
Indeed, it has been reported that TDMD occurs to a higher degree in primary neurons
compared to fibroblasts (de la Mata et al., 2015), but it remains to be seen if RNAmediated degradation of miRs can fully explain rapid turnover kinetics. Our data showed
that elimination of the cellular proteins, but not RNAs, through pre-digestion with
proteinase K was sufficient to stabilize the normally rapidly degraded miRs for up to four
hours (Fig. 6A, B), raising the possibility that the primary contribution of other cellular
RNAs is to recruit the proteins required for miR degradation.
Our data using brain tissue lysate would suggest that miR-9-5p and miR-9-3p are
degraded on a seconds-to-minutes time scale, respectively. However, Winter and
Diederichs showed that the expression of AGO proteins was critical in determining
global miR stability (2011), and we estimated that less than 10% of our input miR were
efficiently loaded onto AGO2 (Fig. 3). Importantly, the loading efficiency was similar for
both miR-9-5p and miR-9-3p, suggesting that the relative stability of miR-9-3p was the
result of differential degradation. However, it is difficult to estimate how much
endogenously expressed miR-9 is loaded onto AGO2 at any given time, and these
numbers have not been reported to our knowledge. Nevertheless, we expect that the
degradation kinetics reported in this study are likely reflective of the mature miR after it
has unloaded from the RNA-induced Silencing Complex (RISC), thus leaving the single
stranded transcript exposed to the cytoplasmic milieu. Notably, Baccarini et al. reported
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that a single miR can be recycled to have multiple mRNA targets, leaving the intriguing
possibility that mature miRs can be reloaded onto AGO proteins after the completion of
their initial RNAi function (2011). Nevertheless, our data provide valuable information
about the cis features of miR-9-5p and miR-9-3p that contribute to differential stability.
This modified assay (Chatterjee et al., 2009) used physiologically relevant levels (10
fmols) of miRs, in the context of cellular factors that are endogenously present in
neurons, thereby allowing us to assess inherent sequence and/or structural features of
each miR that contributes to stability. Our data clearly demonstrate that in brain tissue,
each miR exhibited different rates of degradation and resulted in different cleavage
products, which were also brain-region specific, despite being subjected to identical
experimental conditions. While it is still unclear which enzyme was responsible for the
degradation that we observed, it is evident that miR-9-5p degradation was directly
correlated with total protein concentration in the lysate based on our dilution
experiments and digestion of proteins with proteinase K (Fig. 6A, B). Furthermore, the
rapid degradation that was observed using tissue lysate suggests that a unique protein
is present in brain tissue lysate compared to homogenous neuronal cell lines, as protein
concentration was held constant for both experiments. In addition, miR-9-5p was
relatively stable in primary astrocytes (Fig. 7B, C), suggesting that the enzyme
responsible for rapid degradation might be unique to neurons or have relatively lower
expression in astrocytes.
Previous studies have used transcriptional inhibition, such as with actinomycin D,
followed by qPCR to profile degradation kinetics of mature miRs (Sethi et al., 2009). Our
own results from transcriptional inhibition studies indicate that miR-9-3p was again more
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stable than miR-9-5p under those conditions; in fact, miR-9-3p levels remained stable
throughout all the time points that were measured (Fig. 4). While these studies are
beneficial in that turnover kinetics can be measured in intact cells, transcriptional
inhibition has been repeatedly shown to negatively affect cellular growth and survival.
Therefore, it remains unclear how the turnover kinetics in these altered physiological
contexts reflect those of native cells. Recent approaches utilizing metabolic labeling can
circumvent many of the obstacles posed by transcriptional inhibition (Marzi et al., 2016).
In those experiments, 4-thiouridine, a nucleoside analogue, is added to the cellular
growth medium and incorporated by nascent RNAs that are actively transcribed. This
analogue is often modified by biotinylation so that it can be efficiently isolated from the
endogenous pool of RNA. The purified transcripts are then quantified by qPCR or other
sequencing methods to determine the steady state of the specific RNA of interest.
However, due to the intrinsic disparity in the uridine content of miR-9-5p and miR-9-3p,
~48% and ~18% respectively, the purification efficiency of biotinylated 4-thiouridine in
each of these miR transcripts is also likely to be different, making it difficult to compare
their rate of degradation. In fact, Rädle and colleagues concluded that short RNA
species with low uridine content are likely to escape biotinylation-mediated precipitation
even at high 4SU starting concentrations (2013).
Although metabolic labeling might best approximate the half-lives of miRs under
normal cellular conditions, it does not easily allow for biochemical manipulations that are
necessary to parse out both cis and trans factors of a specific RNA that could be
important for determining its degradation kinetics. For instance, our data indicated that
simply altering 3 nucleotides at the 3’ end was sufficient to alter the degradation kinetics
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of both miR-9-5p and -3p to an intermediary degradation rate (Fig. 8C), suggesting that
the 3’ end of mature miR-9 represents a critical motif for protein interaction. Indeed,
multiple reports from the literature suggest that the 3’ end of miRs are an essential
element. For example, the 3’ terminal 7 nucleotides of miR-382 were observed to be
necessary for its rapid decay (Bail et al., 2010). Furthermore, the terminal 3’ nucleotide
has been shown to be monoadenylated by GLD2 causing a stabilizing phenotype in a
subset of miRs expressed in human fibroblasts (D’Ambrogio et al., 2012); however,
GLD2-catalyzed monoadenylation of miRs had no stabilizing effect in the hippocampus,
providing further evidence of tissue specific regulatory pathways (Mansur et al., 2016).
In Arabidopsis thaliana, a 3’ to 5’ exoribonuclease (Atrimmer) has been shown to be
critical for miR turnover (Wang et al., 2018), whereas the 3’ to 5’ exoribonuclease,
DIS3L2, was observed to degrade miRs in mammalian cell lines (Haas et al., 2016),
further supporting the notion that the 3’ terminus can serve as a critical recognition
element in miR processing and degradation. Interestingly, our data showed that the 5’
uracil of miR-9-5p was also important for conferring stability, as removal of this
nucleotide, representing an endogenous miR-9-5p isomiR, resulted in enhanced
stability compared to the canonical sequence (Fig. 8D). This finding is interesting in the
context of recent reports demonstrating that this miR-9-5p isomiR can be generated by
alternative Drosha cleavage of primary miR-9 (Bofill-De Ros et al., 2018). This isomiR
shifts the seed sequence of the miR, thereby expanding the scope of its respective
mRNA targets. Functionally, it was identified that prevalence of this miR-9-5p isoform
correlated with tumor progression in low-grade glioma (Bofill-De Ros et al., 2018),
suggesting that its inherent stability could contribute to unhinged, and even detrimental,
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downstream consequences in neural pathophysiology. Our degradation assays showed
that little, if any, degradation of miR-9-5p and -3p occurred at the 5’ end, based on total
densitometry of all bands, including the smaller degradation products, between the
initial to the final timepoint. However, Meziane and colleagues showed that the
decapping enzyme DcpS was critical in determining the degradation kinetics of miRs by
recruiting the 5’ to 3’ exoribonuclease XRN2 to the processing site in both C. elegans
and in human model systems (2013, 2015), allowing for the possibility of XRN2 is a
contributor of 5’-initiated miR-9-5p and -3p degradation. These cis contributions of even
single nucleotides in altering degradation kinetics propose the exciting possibility that
other neuronal miRs, which vary in their nucleotide compositions, may all exhibit unique
degradation profiles in the central nervous system.
Overall, we have shown that miR-9-5p degradation kinetics are likely very rapid
in the intact rat brain, consistent with previous studies. However, miR-9-3p (passenger)
degradation had not been previously characterized, and our data indicate that the
passenger strand is more stable than the guide in neuronal cells, suggesting that it
could have a more prominent role in the regulation of neuronal physiology. Furthermore,
we provide evidence that the differential degradation kinetics of miR-9-5p and miR-9-3p
can be explained, in part, by both cis and trans elements, underscoring the complexity
of miR degradation in the central nervous system.

CHAPTER FOUR
E2 DIFFERENTIALLY STABILIZES MIR-9-3P IN THE AGING FEMALE BRAIN
Introduction
The ovarian hormone, 17-estradiol (E2), has been shown to upregulate
protective processes in the central nervous system; however, this protection is lost
following the menopausal transition into advanced age (Zarate et al., 2017). The
prolonged absence of circulating E2 is, therefore, problematic, and has been linked to
cognitive decline and an increased risk for dementia. As a result, hormone replacement
therapy is often provided as a clinical alternative to replenish circulating levels of E2 for
menopausal women. However, meta analyses of clinical data supported the “Timing
Hypothesis”, which stated that E2 replacement therapy was only efficacious within a
critical window of time following menopause. These data suggested that there was a
biological switch in E2 action that was temporally dependent (Maki et al., 2013). The
molecular mechanisms underlying this switch in E2 action are the focus of ongoing
research.
miRNAs are an attractive candidate to mediate these disparate effects of E2, as
they can posttranscriptionally regulate up to 60% of all cellular proteins (Friedman et al.,
2009). As such, miRNAs are potent regulators of gene expression, allowing for cells to
adapt to a variety of internal and external stimuli. Aging elicits a complex array of
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cellular changes, many of which involve processes that protect the cell against agerelated damage (DiLoreto et al., 2015]. In addition, certain miRNAs are hormone
responsive in an age dependent manner. Specifically, miR-9-5p and miR-9-3p were
differentially regulated by E2 in the hypothalamus and hippocampus of aged female rats
(Rao et al., 2013, 2015). This finding was particularly relevant due to the extensively
characterized roles of these miRs in maintaining healthy neuronal function through their
regulation of processes involved in neuronal differentiation, dendritic branching, and
even apoptosis (Coolen et al., 2013; Giusti et al., 2014; Davis et al., 2015; Xue et al.,
2016; Sim et al., 2016; Wei et al., 2016). Notably, the ability of E2 to regulate these
miRs in the aged rats depended on the length of time between ovarian hormone
depletion (via ovariectomy) and the subsequent timing of E2 treatment (Rao et al.,
2015), further supporting the notion that differential regulation of miR-9-5p and -3p
could, in part, explain the disparate functional outcomes of E2 treatment
postmenopause.
microRNA regulation by E2 can theoretically be achieved at multiple steps in the
miR biogenesis pathway. Briefly, miR biogenesis is initiated by the transcription of a
long primary transcript (pri-miR) which is subsequently cleaved by the RNase III
enzyme (Drosha) to form the precursor (pre-miR); after nuclear export, pre-miR is
cleaved by another RNase III enzyme (Dicer) to form the miR duplex which contains the
20-23 nt mature miR product (Ha et al., 2014). To date, the investigation of E2
regulation of miRs has primarily been focused on transcription. Transcriptional
regulation of miRs is conceptually reasonable, and somewhat expected, due to the
canonical E2 signaling pathways which involve the activation of nuclear receptors that
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act as transcription factors to initiate or inhibit gene expression. Indeed, there have
been multiple reports suggesting that E2 can have a downstream transcriptional effect
on miRs. For example, E2-bound estrogen receptor  (ER) was found to inhibit the
transcription of pri-miR-30a in a breast cancer cell line (MCF7) by binding to two
proximal sites near its transcription initiation start site (Paris et al., 2012). Furthermore,
in the MCF7 cell line, a widespread decrease in miR expression was also observed
following E2 treatment, suggesting that the ER-mediated inhibition of transcription
could be a shared, global mechanism to downregulate miR expression in an oncogenic
system (Maillot et al., 2009).
In the brain, global decreases in miR expression following E2 treatment have not
been observed, contrary to data from cancer cell lines. In fact, only a subset of 7 miRs
were altered by age and E2 treatment in the brain; and miR-9-5p and miR-9-3p
expression was increased—rather than decreased—in an age and brain region-specific
manner (Rao et al., 2013, 2015). However, E2 treatment did not affect the pri- or premiR-9 levels, suggesting that E2 regulation of miR-9-5p and miR-9-3p was not at the
level of transcription or processing (Rao et al., 2015). Therefore, the objective of this
study was to determine if E2 can regulate miR-9-5p and -3p at the posttranscriptional
level, namely through stabilization of the mature transcript. We hypothesized that E2
regulates miR-9-5p and -3p through stabilization of the mature miR in an age dependent
manner. We tested this hypothesis using a biochemical approach using neuronal cell
lines and hypothalamic tissue isolated from aged female rats. Collectively, our results
indicate that E2 treatment specifically stabilizes miR-9-3p in the rat hypothalamus, and
this stabilization is dependent on both the duration and age of treatment. These data
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contribute to the current understanding of the “molecular switch” of E2 action that
occurs postmenopause by illuminating novel hormonal triggers affecting miR
degradation.
Results
E2 Stabilized MiR-9-3p in a Hypothalamic Cell Line
We used a basic biochemical approach to first determine whether E2 stabilizes
miR-9-5p and miR-9-3p in neuronal cell lines. First, hypothalamic (PVN) derived
neuronal cells (IVB) were treated with 100 nM E2 for either 2 or 15 hours to elicit either
transcriptional and translational changes to the cellular environment mediated by
endogenous estrogen receptors. Subsequently, cells were lysed using a mild lysis
buffer (NP-40), and 32p-labeled oligonucleotide sequences identical to mature miR-9-5p
and miR-9-3p were added to the lysate for the following time points (0, 15, 60, 120, 240
min). Our results showed that E2 treatment did not stabilize miR-9-5p at either
treatment duration (Fig. 11 A,B,C). Conversely, E2 treatment stabilized miR-9-3p in the
IVB cell lysate only at the 15, but not with 2-hour treatment duration (Fig. 11D, E, F). A
comparison of the mean half-lives derived from the best-fit exponential decay functions
indicated that miR-9-3p was approximately twice as stable following 15-hour E2
treatment (Fig. 11F), suggesting that E2-mediated translation of miR degradation
factors are required for stabilization, and that a 2-hour treatment was not long enough to
elicit this response.
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Figure 11. 15 HR E2 Treatment Stabilized MiR-9-3p in a Hypothalamic Cell Line. A)
Representative gel images of miR-9-5p degradation over time (min.) following
incubation in vehicle or E2 treated hypothalamic-derived neuronal cell (IVB) lysate for 0,
15, 60, 120, or 240 min. E2 treatment was at a 100nM concentration for either 2 or 15
hours. B) Scatterplot of normalized densitometry values analyzed from gel images and
fit with an exponential decay function (black line = vehicle; red line = E2; N = 4/group).
C) Mean half-lives of miR-9-5p derived from best-fit exponential decay functions.
Results are represented as mean ± SEM (N = 4/group) and analyzed using a twosample t-test. D) Representative gel images of miR-9-3p degradation over time (min.)
following incubation in vehicle or E2 treated hypothalamic-derived neuronal cell (IVB)
lysate for 0, 15, 60, 120, or 240 min. B) Scatterplot of normalized densitometry values
analyzed from gel images and fit with an exponential decay function (black line =
vehicle; red line = E2; N = 4/group). C) Mean half-lives of miR-9-3p derived from best-fit
exponential decay functions. Results are represented as mean ± SEM (N = 4/group)
and analyzed using a two-sample t-test. * indicated p < 0.05.

E2 Did Not Alter the Expression of Enzymes in the MiR Biogenesis Pathway in
Cell Lines
To determine the contribution of E2 to miRNA biogenesis or processing, which
would be upstream of miR stabilization, mRNA expression of well characterized
enzymes in the biogenesis pathway were investigated in the hypothalamus-derived
neuronal cell lines (IVB). RT-qPCR analysis revealed that mRNA levels of Ago2, Xrn2,
Drosha, Dgcr8, Exportin5, and Dicer were all unchanged with E2 treatment at either
treatment duration (Fig 12), suggesting that these mRNA transcripts are not directly
regulated by the estrogen signaling pathway. These results are in support of previous
studies showing no regulation of processing machinery by E2 treatment in the central
nervous system (Rao et al., 2015), further suggesting that E2 regulation of miRs is not
mediated by altering miR biogenesis or processing pathways.
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Figure 12. E2 Treatment Did Not alter MRNA Levels of MiR Processing Machinery
in a Hypothalamic Cell Line. RT-qPCR results depicting fold change of Drosha, Dgcr8,
Xpo5, Dicer, Ago2, and Xrn2 mRNA in the IVB cell line with vehicle/E2 treatment for 2
hours. Results are represented as mean ± SEM (N = 4/group) and analyzed using a
two-sample t-test. * indicated p < 0.05.

E2 Stabilized MiR-9-3p in OVX Model of Menopause
To further investigate the E2-mediated stabilization of miR-9-5p and miR-9-3p in
the context of the timing hypothesis, the miR degradation assay was repeated using
PVN lysate from our animal model of menopause. Briefly, aged female rats (18 MO)
were ovariectomized to surgically remove the primary source of ovarian hormone
production. Next, to investigate the temporal dependence of age in E2’s ability to
stabilize miR-9-5p and miR-9-3p, E2 was subcutaneously injected either 1 or 12 weeks
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post-OVX. In accordance with our cell line data, E2 exhibited a stabilizing effect for miR9-3p, but not miR-9-5p (Fig. 13A-F). Specifically, there was a distinct increase in the
signal of full length miR-9-3p with E2 treatment at the 1-minute time point (Fig. 13D, F).
Furthermore, this stabilization was limited to treatment that was administered 1 week
following OVX, indicating an age dependent effect of E2. Both miR-9-5p and miR-9-3p
exhibited extremely rapid degradation kinetics in brain tissue lysate relative to the what
was observed in cell lines in support of previous findings (Sethi et al., 2009; Kim et al.,
2020).
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Figure 13. E2 Treatment Stabilized MiR-9-3p in the PVN of Aged Female Rats in an
Age Dependent Manner. A) Representative gel images of miR-9-5p degradation over
time (min.) following incubation in PVN lysate of vehicle or E2 treated rats for 0, 15, 60,
120, or 240 min. Treatment consisted of subcutaneous injections of 2.5 g/kg of E2
dissolved in safflower oil. Injections were administered 1 or 12 weeks following OVX,
once/day for 3 consecutive days prior to euthanasia. B) Scatterplot of normalized
densitometry values analyzed from gel images and fit with an exponential decay
function (black line = vehicle; red line = E2; N = 7/group). C) Mean half-lives of miR-9-5p
derived from best-fit exponential decay functions. Results are represented as mean ±
SEM (N = 4/group) and analyzed using a two-sample t-test. D) Representative gel
images of miR-9-3p degradation over time (min.) following incubation in PVN lysate of
vehicle or E2 treated rats for 0, 15, 60, 120, or 240 min. E) Scatterplot of normalized
densitometry values analyzed from gel images and fit with an exponential decay
function (black line = vehicle; red line = E2; N = 7/group). F) Mean half-lives of miR-9-3p
derived from best-fit exponential decay functions. Results are represented as mean ±
SEM (N = 4/group) and analyzed using a two-sample t-test. * indicated p < 0.05.

E2 Did Not Alter the Expression of Enzymes in the MiR Biogenesis Pathway in
OVX Model
Next, we investigated the contribution of E2 to miRNA biogenesis or processing
that could be occurring in the PVN of aged female rats. mRNA expression of well
characterized proteins in the miR biogenesis pathway were investigated using RNA
isolated from the PVN. In accordance with the data observed in cell lines, E2 treatment
did not affect mRNA expression of Ago2, Xrn2, Dgcr8, Exportin5, or Dicer at both the 1
week and 12 week time points (Fig. 14 A, B). One exception, however, was that E2
significantly decreased Drosha mRNA levels at the 1, but not, 12 week time point (Fig.
14 A, B), raising the possibility that global processing of primary miRs could be altered
with E2 treatment in the PVN with early intervention.
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Figure 14. E2 Treatment Generally Did Not alter MRNA or Protein Levels of MiR
Processing Machinery in the PVN of Aged Female Rats. RT-qPCR results depicting
fold change of Drosha, Dgcr8, Xpo5, Dicer, Ago2, and Xrn2 mRNA in the PVN of aged
female rats with vehicle/E2 treatment A) 1 or B) 12 weeks following OVX. Results are
represented as mean ± SEM (N = 6/group) and analyzed using a two-sample t-test. *
indicated p < 0.05.
E2 Altered Protein Expression in the Rat PVN
We then investigated proteins that were significantly altered with E2 treatment at
the 1-week time point to identify the E2-regulated stabilizing factor for miR-9-3p. Protein
samples were prepared from the PVN of vehicle and E2 treated rats for mass
spectrometry (N of 3/ treatment group). Peaks software analysis revealed that there was
a total of 18 proteins that were significantly altered with treatment (Fig. 15A). Among the
proteins of interest that were upregulated was Serine and Arginine Rich Splicing Factor
2, or Srsf2.

Figure 15. E2 Treatment 1 Week Following OVX Altered Protein Expression in the
PVN. A) Heat map depicting significantly regulated (p<0.05) proteins in the PVN of 18month-old rats given vehicle or E2 treatment 1 week following OVX. Protein expression
is represented using a color code where red and green represents upregulation and
downregulation respectively (N = 3/group). B) Sequence of miR-9-3p with the Srsf2
consensus binding motif indicated in green.
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Srsf2 is an RNA binding protein that has been implicated in pre-mRNA splicing.
While it has not previously been characterized to associate with miRs, a close
approximation to the consensus Srsf2 nucleic acid binding motif was present within
miR-9-3p sequence (Fig. 15B). Therefore, we speculated that an E2-mediated increase
in Srsf2 expression would augment protein binding to miR-9-3p, which in turn, would
afford the miR protection from exoribonucleases. Therefore, we aimed to validate
whether Srsf2 expression—both at the mRNA and protein level—would change with
age and E2 treatment. In the PVN, Srsf2 mRNA expression was unchanged by E2
treatment 1-week post-OVX; however, E2 treatment 12 weeks post-OVX significantly
downregulated Srsf2 mRNA, again displaying an age dependent effect of E2 (Fig. 16A).
Protein expression of Srsf2, however, was unchanged with E2 treatment at either time
point (Fig. 16B, C). Therefore, the E2-mediated stabilization of miR-9-3p at the 1wk time
point is not likely mediated by Srsf2.
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Figure 16. E2 Treatment Did Not Alter Srsf2 Protein Expression in the PVN of
Aged Female Rats. A) RT-qPCR results depicting fold change of Srsf2 mRNA in the
PVN of aged female rats with vehicle/E2 treatment 1 or 12 weeks following OVX.
Results are represented as mean ± SEM (N = 5/group) and analyzed using a twosample t-test. B) Representative western blot images of Srsf2 and β-actin. 30 g of
protein was subject to electrophoresis on a 10% polyacrylamide gel (N = 6/group). C)
Quantification of averaged densitometry values. Data are represented as mean fold
change ± SEM (N = 6/group) and analyzed using a two-sample t-test. * indicated p <
0.05.
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E2 Altered MiR-9-5p and 3p Downstream Targets
Next, we examined the downstream consequences of E2-mediated miR
stabilization by assaying for the expression of validated miR-9-5p and miR-9-3p targets:
Gabrb2 and Sap97 respectively (Bofill-De Ros et al. 2019; Sim et al., 2016). Gabrb2, or
GABA(A) receptor beta subunit 2, comprises a pentameric chloride channel that is
generally inhibitory to action potential propagation, and its dysregulation has been
linked to various neurodegenerative diseases (Chen et al., 2009; Yeung et al., 2018).
Sap97, or synapse associated protein 97, has been implicated in pathologies such as
schizophrenia, as it primarily acts as an anchor protein at the synapse to inhibit long
term potentiation (Fourie et al., 2014; Gupta et al., 2018). Taken together, the precise
regulation of both of these proteins are crucial for maintaining normal neuronal function.
Therefore, we speculated that E2-mediated miR stability would allow for more effective
downregulation of the respective mRNA target.
In the IVB cell lines, E2 treatment had no effect on the miR-9-5p (Gabrb2) or
miR-9-3p (Sap97) target mRNA expression at either treatment duration (2HR/15HR)
(Fig. 17A,B). In contrast, in the animal model of menopause, E2 treatment significantly
reduced mRNA expression of Gabrb2 at the 1-week, but not, 12-week time point (Fig.
18A). Similarly, E2 treatment exhibited a trend towards a decrease in the mRNA
expression of Sap97 at the 1-week time point, again indicating an effect of E2 that was
dependent on the timing of administration (Fig. 19A). However, the protein expression
of Gabrb2 and Sap97 in the PVN were unchanged with E2 treatment at both time points
(Fig. 18B, C; Fig. 19B, C), suggesting that the translation of these specific targets was
not affected by miR stabilization.
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Figure 17. E2 Treatment Did Not Alter Gabrb2 and Sap97 MRNA Expression in a
Hypothalamic Cell Line. A) RT-qPCR results depicting fold change of Gabrb2 and B)
Sap97 mRNA in the IVB cell line with vehicle/E2 treatment for 2 or 15 hours. Results
are represented as mean ± SEM (N = 6/group) and analyzed using a two-sample t-test.
* indicated p < 0.05.
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Figure 18. E2 Treatment Reduced Gabrb2 MRNA 1 Week Following OVX. A) RTqPCR results depicting fold change of Gabrb2 mRNA in the PVN of aged female rats
with vehicle/E2 treatment 1 or 12 weeks following OVX. Results are represented as
mean ± SEM (N = 5/group) and analyzed using a two-sample t-test. B) Representative
western blot images of Gabrb2 and β-actin. 30 g of protein was subject to
electrophoresis on a 10% polyacrylamide gel (N = 6/group). C) Quantification of
averaged densitometry values. Data are represented as mean fold change ± SEM (N =
6/group) and analyzed using a two-sample t-test. * indicated p < 0.05.
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Figure 19. E2 Treatment Reduced Sap97 MRNA 1 Week Following OVX. A) RTqPCR results depicting fold change of Sap97 mRNA in the PVN of aged female rats
with vehicle/E2 treatment 1 or 12 weeks following OVX. Results are represented as
mean ± SEM (N = 5/group) and analyzed using a two-sample t-test. B) Representative
western blot images of Sap97 and β-actin. 30 g of protein was subject to
electrophoresis on a 10% polyacrylamide gel (N = 6/group). C) Quantification of
averaged densitometry values. Data are represented as mean fold change ± SEM (N =
6/group) and analyzed using a two-sample t-test.
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Discussion
The molecular mechanisms underlying the disparate effects of hormone
replacement therapy as postulated by the timing hypothesis are still being explored. In
the present study, we describe the novel finding that E2 treatment can regulate mature
miRs in an age dependent manner. Our current view of E2 regulation of miRs are
focused at the transcriptional level mediated by the actions of estrogen receptors on
ERE (estrogen response elements) upstream of miRs. Here, we use a biochemical
approach to reveal that E2 treatment can posttranscriptionally regulate the stability of
mature miRs in both cell lines and in the PVN of aged, female rats. Specifically, E2
stabilized miR-9-3p which has been shown to be important for driving not only neuronal
differentiation, but also for regulating synaptic plasticity in post-mitotic neurons (Sim et
al., 2016). Furthermore, this E2-mediated stability was only evident with early
intervention in our OVX paradigm using aged female rats, revealing a novel mechanism
of miR regulation that could contribute to the molecular mechanism underlying the
timing hypothesis.
Our data are consistent with previous reports describing rapid miR degradation in
the central nervous system (Krol et al., 2010; Sethi et al., 2009; Kim et al., 2020). Here,
we demonstrated that miR-9-5p and miR-9-3p degrade in a seconds to minutes time
scale in hypothalamus derived neuronal cell lines and in the PVN of aged female rats
(Fig. 11C,F; Fig. 13C,F). However, it is important to consider that the half-lives derived
from this study are not necessarily reflective of endogenous miR half-lives, as the lysis
process required for the degradation assay disrupts the subcellular organization of its
molecular constituents, thus potentially introducing processes that would not occur in an
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endogenous setting. Nevertheless, it is evident from the obtained biochemical data that
E2 treatment is altering the cellular milieu in such a way that is protective for miR-9-3p,
but not miR-9-5p.
Therefore, in search of this stabilizing molecular factor, we performed mass
spectrometry on the proteins isolated from the PVN of both vehicle and E2 treated rats
to identify which proteins were significantly altered with E2 treatment. Among the
significantly regulated proteins, Srsf2 was an RNA binding protein of interest because
its consensus binding motif was present within the miR-9-3p sequence (Zhang et al.,
2015). However, subsequent validation by western blot analysis revealed that Srsf2
protein expression did not change with age and treatment (Fig. 16A-C). Therefore, the
E2-mediated stabilizing factor for mir-9-3p is likely unrelated to the Srsf2 pathway, and
further validations of other significantly regulated protein hits from the mass
spectrometry data will be the focus of future research.
Estrogens initiate cellular signaling processes via their interaction to nuclear
receptors: ER and ER (Fuentes and Silveyra, 2019). The stabilizing effect of E2 that
was observed for miR-9-3p in our cell and tissue models is likely mediated by the
actions of ER. In the IVB cell lines, ER is dominantly expressed, though ER
expression can still be observed (Ogura et al., 2008; Handa et al., 2012). Additionally,
previous research in the lab has demonstrated that miR-9-3p expression was
responsive to an ER-specific agonist (diarylpropionitrile: DPN), but not an ER-specific
agonist (propylpyrazole-triol: PPT) in the rat hypothalamus (Rao et al., 2015).
Furthermore, ER has recently been shown to indirectly interact with Argonaute2
(Ago2) in breast cancer cell lines, suggesting a role for ER in RISC loading (Tarallo et
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al., 2017). Since miR loading to Ago2 has been positively correlated with stabilization of
the miR (Winter and Diederichs, 2011), it remains an intriguing possibility that ER is
facilitating the loading of miR-9-3p to the RNA-induced silencing complex (RISC).
Furthermore, distinct miR profiles were observed between ER positive and negative
breast cancer cell lines (Paris et al., 2012), further supporting the notion that ER
signaling is critical in the regulation of a specific subset of miRs.
Furthermore, we postulate that the E2 regulation of miR-9-3p is executed at the
mature level and not at the level of transcription. These results are novel as numerous
reports have shown E2 to regulate various aspects of miR biogenesis. For instance,
estrogen receptors have been shown to directly bind to the promotors of miR genes to
regulate the transcription of primary miRs (Di Leva et al., 2010; Paris et al., 2012).
Indirect regulation of miR transcription has also been reported whereby steroid signaling
mechanisms have been shown to recruit other transcription factors to miR promoter
sites; specifically, c-MYC was recruited to the promotor site of miR-17-92 (Castellano et
al., 2009). In general, E2 treatment has been associated with the transcriptional
repression of miRs, especially when the precursor strand harbors a G-rich terminal loop
(Maillot et al., 2009; Cohen et al., 2017). However, it is important to consider that most
of these studies were performed within reproductive tissues, and E2 regulation of miRs
in the central nervous system is notably distinct from peripheral tissues. While E2
treatment upregulated levels of mature miR-9-5p and miR-9-3p in the rat hypothalamus,
the primary and precursor levels remained unchanged (Rao et al., 2015), suggesting
that this upregulation was not mediated by an increase in transcription.
Moreover, we generally observed no effect of E2 treatment to the miR processing
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machinery in both cell lines and in the PVN of aged female rats (Fig. 12, Fig. 14A, B).
One exception was a significant reduction in Drosha mRNA levels with E2 treatment 1week post-OVX (Fig. 14A). These results are again in contrast to the well characterized
effect of E2 on the various aspects of miR processing in reproductive tissues. For
instance, ER has been shown to bind and inhibit the enzymatic activity of Drosha
(Paris et al., 2012). Estrogen and progesterone signaling together increased Exportin5
mRNA expression in mouse uterine tissue, and Dicer expression has been observed to
be increased with E2 treatment in MCF7 cells. (Nothnick et al. 2010; Bhat-Nakshatri et
al., 2009). Furthermore, ER positive cell lines had increased Dicer and decreased Ago2
expression compared to ER negative cell lines (Cheng et al., 2009). In our system, we
observed no such E2-mediated changes to the miR processing machinery (Fig. 12, Fig.
14A, B), suggesting that miR processing has not been altered by E2 treatment.
Therefore, E2 regulation, at least in the aged rat hypothalamus, is likely not mediated by
altering the transcription or the processing of miRs; rather, E2 seems to exert its actions
directly at the level of mature miR, specifically via stabilization.
Next, we speculated that the E2-mediated stabilization of miR could elicit
significant downstream cellular consequences, especially in light of the rapid miR
degradation reported in the brain (Sethi et al., 2009; Krol et al., 2010; Kim et al., 2020).
Elongating the half-life of these rapidly degraded miRs would theoretically afford it more
time to repress their mRNA targets. Therefore, we investigated the mRNA targets of
both miR-9-5p and miR-9-3p with the expectation that the miR-9-3p target could be
significantly downregulated with E2 treatment, since miR-9-3p was stabilized by E2.
While target mRNA (Sap97) levels were downregulated with E2 treatment as expected
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(Fig. 19A), protein levels remained unchanged (Fig. 19B). One interpretation of the
discordance in the mRNA and protein data is that the samples were acquired from one
snapshot in time, which could have preceded the reduction of protein expression at a
later timepoint. Additionally, miR and target mRNA relationships often stray from the
predicted stoichiometric relationships, as mRNA targets are under the regulation of
many other upstream cellular signals. Furthermore, there are hundreds of in silico
predicted mRNA targets and several experimentally validated mRNA targets for miR-93p (Table 7), so the potential downstream effects of its stabilization still remain to be
seen.
The molecular switch underlying the timing-dependent effects of E2 is likely
represented by a convergence of multiple signaling pathways. Here, we identify another
potential molecular component to this switch in E2 action, namely via stabilization of
mature miR-9-3p which is observed with early, but not late, E2 administration. Due to
the importance of miR-9-3p in governing normal neuronal function (Sim et al., 2016), the
results reported herein allow for new avenues of research in understanding how
differential miR stabilization can determine the efficacy of hormone replacement
therapy, particularly in the central nervous system of postmenopausal women.
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Table 7. Table of Experimentally Validated MRNA Targets of MiR-9-5p and MiR-93p. Validated targets were identified by miRTarBase. Only targets that have been
validated by reporter assay, western blot, or RT-qPCR are represented.

miRNA
miR-9-5p

miR-9-3p

Validated targets
CCND1, FOXO3, ID2,
SOC55, TGFB1, SIRT1,
SRF, MMP13, REST,
CDH1, STMN1, POU2F2,
BCL6, ETS1, RAB34,
BACE1, FOXG1, PRDM1,
HER9, NFKB1, RUNX1,
HER5, GABRB2, FGFR1a,
CNPY1, FGF8a, NR2E1,
ONECUT2, FOXP1,
CDX1, HES1, ZFPS21,
AP3B1, CCNG1
RCOR1, SAP97, ITGB1,
GNAI1

CHAPTER FIVE
17-ESTRADIOL (E2) ALTERS THE SUBCELLULAR LOCALIZATION OF MIR-9-5P
AND MIR-9-3P
Introduction
miRNAs have been discovered to be localized within various cellular
compartments. Surprisingly, miRNAs have even been found in the nucleus (Barthelson
et al., 2007), although their canonical action of translation inhibition occurs in the
cytoplasm. Specifically, miR-29b was found to be enriched in the nucleus harboring a
specific hexanucleotide localization motif at the 3’ end. This motif was found to be
critical for nuclear localization, as an unrelated 21-nucleotide RNA was engineered to
localize to the nucleus with this same hexanucleotide sequence (Hwang et al., 2007).
Interestingly, recent studies have shown that most miRNAs are actually present at some
level in both the nucleus and cytoplasm (Liao et al., 2010; Jeffries et al., 2011). This
finding is further supplemented by the discovery of a major miRNA binding protein,
Argonaute 2 (AGO2), in the nucleus. However, AGO2 exists in a 158 kDA complex in
the nucleus, while it exists in a 3 MDa complex in the cytoplasm (Ohrt et al., 2008). This
leaves the intriguing possibility that nuclear AGO2 can bind miRNA either outside of the
RNA induced silencing complex (RISC) and/or in a complex drastically smaller than the
RISC present in the cytoplasm. More remarkably, all 4 AGO isoforms – which are

92

93
mostly functionally redundant in their silencing capability –have been recently found to
be shuttled to the nucleus to some extent, further suggesting a nuclear role of miRNAs
(Pitchiaya et al., 2017).
The nuclear functions of miRNAs are most likely different than its cytoplasmic
counterparts due to the availability of substrates. For example, in the nucleus, miRNAs
have been proposed to bind to DNA to initiate or repress transcription by changing DNA
topography and subsequently altering the recruitment of transcription factors, whereas
the cytoplasmic functions of miRNAs are purely post-transcriptional (Liu et al., 2018).
Due to their starkly different functions, it is intuitive that the homeostatic balance of
nuclear to cytoplasmic miRNA would be critical to proper neuronal health and function.
However, there is considerable evidence from the literature to suggest that this intricate
balance can be disrupted with stress and age.
For instance, the nuclear pore complex, comprised of highly organized structures
called nucleoporins, has been shown to be disorganized with age (Sakuma et al., 2017).
Nucleoporins have rotational symmetry allowing it to mediate nucleo-cytoplasmic
transport of both protein and RNA. In the case of miRNAs, phosphorylation of nuclear
pore complex protein 153 (NUP153) by ERK leads to pre-miRNA being retained in the
nucleus (Williams et al., 2017). Therefore, it can be inferred that the aberrant kinase
signaling and subsequent disruptions to the integrity of the pore complex that occurs
with age can also lead to suboptimal miRNA localization. Furthermore, due to 17βestradiol’s known role in regulating the nuclear transport of estrogen receptors upon
dimerization, it is likely that 17β-estradiol also has a role in regulating the nuclear to
cytoplasmic localization of miRNAs in the context of aging. This represents the
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intriguing possibility that the molecular switch of estrogen action in HRT, could be in
part, mediated by altering the subcellular localization of neuroprotective miRNAs.
Therefore, the objective of these experiments was to determine if miR-9-5p and 3p subcellular localization is altered after E2 treatment. We hypothesized that more
miR-9-5p and -3p will be localized in the cytoplasm following E2 treatment. The
rationale for this hypothesis was based off of evidence from the literature suggesting
that miR-9-5p and miR-9-3p have critical roles in maintaining neuronal health in the
cytoplasm; therefore, it follows that with E2 administration where neuroprotection is
observed, these miRNAs should be exerting these neuroprotective functions in the
cytoplasmic compartment. This hypothesis operates under the assumption that nuclear
localization of miR-9-5p and -3p prohibits these neuroprotective functions.
Using the IVB hypothalamic cell line, differential fractionation was utilized to isolate
nuclear and cytoplasmic RNA. Briefly, IVB cells were once again incubated with either
E2 or vehicle treatment as described in Chapter 3, Experiment 1. After treatment, the
cell lysates were subjected to differential centrifugation to isolate the nuclear and
cytoplasmic RNA fractions (Fig. 7). The obtained RNA was reverse transcribed, and RTqPCR was performed with nuclear and cytoplasmic cDNA in both E2-treated and
vehicle-treated conditions to measure levels of mature miR-9-5p and miR-9-3p. Our
results indicated that E2 can increase nuclear levels of both miR-9-5p and miR-9-3p,
revealing a novel mechanism of hormonal regulation that would not necessitate a
change in miRNA expression. These studies demonstrate that miRNAs can be
regulated simply by changing its localization to different foci within the cell.
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Results
E2 Increases Levels of Both MiR-9-5p and MiR-9-3p in the Nucleus
To investigate whether E2 treatment can alter the subcellular localization of miR9-5p and miR-9-3p, hypothalamus derived neuronal cells (IVB) were treated with vehicle
or E2 treatment (100uM). Two treatment durations were tested: 2 HR and 15 HR to
allow for enough time for transcriptional and translational changes mediated by the
estrogen receptors (ERs). Following treatment, cells were differentially centrifuged to
isolate the nuclear and cytoplasmic fractions. Genomic DNA was only observed in the
nucleus and ribosomal RNA was enriched in the cytoplasmic fraction as expected (Fig.
20A). Furthermore, RNU1A, a nuclear RNA, was only detectable in the nuclear or whole
cell fractions but not in the cytoplasmic fraction (Fig. 20B). Furthermore, 18s rRNA, a
ribosomal RNA, was significantly enriched in the cytoplasmic fraction compared to the
nuclear fraction (Fig. 20C), further providing evidence of the purity of fractionation.
Next, RNA that was isolated from the nuclear and cytosolic fractions and reverse
transcribed for RT-qPCR analysis to determine the effect of E2 on the subcellular
localization of miR-9-5p and miR-9-3p. 2-hour E2 treatment had no effect on nuclear or
cytoplasmic levels of either miRNA (Fig. 21 A, B). However, a 15-hour treatment
duration increased nuclear levels of both miR-9-5p and miR-9-3p (Fig. 21 A, B),
suggesting that estrogen mediated signaling was allowing for alterations in protein
expression that changed the subcellular organization of these miRNAs.
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Figure 20. Validation of Nuclear and Cytosolic Fractionation. A. IVB nuclear and
cytoplasmic RNA run on a 1.5% agarose gel. Nuclear fraction contains genomic DNA
with minimal ribosomal RNAs, and the cytoplasmic fraction contains 28s and 18s rRNA
bands. B. RT-qPCR products for RNU1A (a nuclear RNA) are visible from nuclear, but
not cytoplasmic RNA fractions. C. 18s rRNA is significantly increased in the cytoplasmic
fraction compared to the nuclear fraction (N=3). * denotes P < .05.
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Figure 21. 15 HR E2 Treatment Increased Nuclear Levels of MiR-9-5p and MiR-93p. A. RT-qPCR results for miR-9-5p in nuclear and cytoplasmic fractions with 2 or 15
HR E2 treatment. B. RT-qPCR results for miR-9-3p in nuclear and cytoplasmic fractions
with 2 or 15 HR E2 treatment. (N=4) * denotes P < .05.
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E2 Treatment Increased Ago2 Bound MiR-9-5p and MiR-9-3p
Next, we investigated the effect of E2 treatment on Ago2 expression, since Ago2
is the primary RNA binding protein of miRNAs. Furthermore, Ago2 has been shown to
translocate to the nucleus to elicit epigenetic programming by interacting with chromatin
remodeling complexes to ultimately regulate downstream gene expression. Therefore,
we speculated that E2 regulation of Ago2 could provide a plausible mechanism for the
differences in subcellular localization of miR-9-5p and miR-9-3p. However, 2 HR E2
treatment had no effect on Ago2 mRNA (Fig. 22A), and a 15-hour E2 treatment had no
effect on Ago2 protein expression in the IVB cell lines (Fig. 22B).
Although protein expression of Ago2 was unaltered by E2 treatment, we
investigated the levels of miR-9-5p and miR-9-3p following immunoprecipitation of Ago2
to determine whether E2 treatment could still affect miR-9-5p and miR-9-3p binding. We
observed increases in the levels of both miR-9-5p and miR-9-3p following E2 treatment
in the Ago2 pulldown when normalized to a 10% input (Fig. 23 A,B,C). Specifically,
54.4% of the miR-9-5p input was immunoprecipitated with Ago2 following E2 treatment
compared to 6% with vehicle treatment. The increase in Ago2-bound miR-9-3p was
more modest; 11.38% of the miR-9-3p input was immunoprecipitated with Ago2 after E2
treatment compared to 0.3% with vehicle treatment (Fig. 23 A,B). Therefore, while E2
treatment increased levels of miR-9-5p and miR-9-3p following Ago2 pulldown, the
magnitude of the increase was specific to the miRNA.
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Figure 22. Ago2 MRNA and Protein was Not Altered by E2 Treatment. A. RT-qPCR
results for Ago2 following 2 HR E2 treatment. B. Representative western blot image
(white; AGO2, green; β-actin). Densitometry analysis of Ago2 band normalized to β actin.
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Figure 23. E2 Treatment Increased Levels of MiR-9-5p and MiR-9-3p
Immunoprecipitated by Ago2. A. RT-qPCR results for miR-9-5p and -3p following
immunoprecipitation with Ago2 antibody with vehicle or E2 treatment. Data is as a % of
the input. Two sample t-test was performed between vehicle and E2 treated samples.
(N=4) * denotes P < .05 B. Representative image of miR-9-5p RT-qPCR products run
out on a 2% agarose gel.
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Discussion
In the present study, we describe the novel finding that E2 treatment can regulate
the subcellular localization of miRNAs—globally to specific subcellular compartments,
but also to specific RNA binding proteins. The current literature supports the presence
of miRs throughout all cellular compartments; however, their regulation to these
compartments is still the focus of ongoing research. Here, we have identified a specific
hormonal signal that regulates the localization of two neuronally enriched miRNAs: miR9-5p and miR-9-3p. Specifically, we observed a significant difference in miR-9-5p and 3p nuclear-to-cytoplasmic localization, dependent on the duration of E2 treatment (2 HR
vs 15 HR), suggesting that estrogen receptor mediated changes to protein expression
may be a prerequisite for the nuclear transport of miR-9-5p and -3p.
To identify all the proteins that were altered with E2 treatment, we lysed and
prepared the IVB cells for mass spectrometry (Appendix A). Interestingly, Importin beta
sub unit1 (KPNB1) was found to be significantly downregulated with E2 treatment at the
15-hour duration. While Exportin 5 (XPO5) is canonically considered to be responsible
for the export of precursor miRNAs to the cytoplasm, the importin protein has recently
been shown to regulate the nuclear transport of mature miRNAs (Wei et al., 2014).
Therefore, the accumulation of miR-9-5p and miR-9-3p in the nucleus is peculiar, since
we also observed a significant reduction in their cognate import protein. A potential
interpretation could be that the cell has already initiated feedback processes to
decrease the nuclear import of mature miRNAs.
The E2-mediated increase in the interaction of miR-9-5p and miR-9-3p to Ago2
suggest that E2 may facilitate the loading of the mature miR-9 duplex which houses
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both of these miRNAs. As this phenomenon was observed within 2 HRs of estrogen
treatment (Fig. 23 A,B), it is likely that non-genomic pathways of E2 are activated to
post-translationally modify Ago2 to selectively load and retain miR-9-5p and -3p. An
intriguing enzyme that is likely to facilitate this process is MAPK, or mitogen activated
protein kinase. This kinase has been previously shown to be differentially regulated by
both age and E2 treatment. Specifically, in the rat PVN, MAPK was significantly
upregulated with E2 treatment 1 week following ovariectomy (Pinceti et al., 2015).
MAPK is responsible for the phosphorylation of serine 387 on the Ago2 protein (Zeng et
al., 2008), which in turn alters the conformation of Ago2 to affect miRNA binding.
However, it is unclear whether MAPK activation of Ago2 would afford the specificity that
was observed in the E2 regulation of miRNAs.
Additionally, Ago2 association has been implicated with stability of the miRNA, as
structural analyses dictate that the 5’ and 3’ ends of the miRNA are embedded within
the protein, shielded from exoribonucleases (Winter et al., 2011). Therefore, E2
mediated stability of miR-9-3p both in cell lines and in our animal model of menopause
could be explained by its enhanced association with Ago2; however, this interpretation
cannot fully explain the lack of miR-9-5p stabilization since its association with Ago2
was also enhanced with E2 treatment. Furthermore, since both miRNA strands were
associated with Ago2 and also increased in abundance in the nucleus (Fig. 21, Fig. 23),
it can be speculated that these miRNAs were shuttled into the nucleus attached to Ago2
as the transport mechanism. Nuclear Ago2 has been implicated in epigenetic and
transcriptomic regulation (Katz et al., 2016), suggesting that both miR-9-5p and miR-93p could also have a role in the nucleus which contrasts from the canonically gene
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silencing mechanisms described in the cytoplasm.
A potential limitation of the proposed work is that only one snapshot in time is
being observed following E2 treatment. Therefore, even if a change in localization is not
seen at the moment of detection for the 2-hour treatment duration, it could still be the
case that E2 treatment is shuttling miRNAs into and out of the nucleus. One way to
observe the active trafficking of miRNAs is to use live cells and microinject custom
miRNA sequences modified with a fluorophore on the 3’ end as performed by Pitchiaya
et al. (2017). After injection, fluorescence microscopy can be utilized to track the
movement of these synthetic sequences with estrogen treatment. However, the
limitation to such an experiment is that the fluorophore itself could disrupt the normal
trafficking of the miRNA, especially due to the relatively small size of the mature miRNA
transcript. Therefore, important control experiments with fluorescently tagged,
nonspecific scrambled sequences must be performed in parallel to determine
nonspecific intracellular movement of the fluorophore.
Additionally, even though we observed that the nuclear to cytoplasmic levels of
miR-9-5p and -3p are unchanged by E2 at the 2-hour treatment duration, this does not
rule out an effect of E2 on miRNA localization to smaller subcellular compartments.
Recently, miRNAs have been discovered in numerous compartments and organelles,
such as the mitochondria, endoplasmic reticulum, polysomes, p-bodies, and stress
granules (Leung 2016). As all of these are distinct foci within the cytoplasm, an E2
mediated allocation of miR-9-5p or miR-9-3p to one of these foci would not be detected
in a whole cytoplasmic assay. Therefore, specific foci within the cytoplasm can be
extracted via differential centrifugation and sucrose gradient fractionation to determine
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the presence of miR-9-5p and -3p in these distinct compartments following estrogen
treatment. To that end, we have successfully identified the presence of miR-9-5p in the
polysomes fractions upon sucrose gradient fractionation of IVB cells (Fig. 24), and
whether E2 can regulate its localization to polysomes will be the focus of future
research.
The data presented in this chapter adds another layer of complexity to the study
of miRNA and the development of miRNA-specific therapeutics. With the knowledge
that hormonal triggers can regulate miRNA turnover and subcellular localization, this
research necessitates the development of miRNA-targeted drugs that are sex specific.
Furthermore, the elucidation of miRNA localization is important for proper understanding
of the homeostatic brain as well as the mechanisms by which miRNA can be involved in
pathological conditions. The research presented herein fills important gaps in our
understanding of miRNA biology and provides an underlying foundation for future
research into hormonal alterations of miRNA stability, localization, and function.
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A.
polysomes

B.

Figure 24. MiR-9-5p was Detectable in the Polysome Fraction. Representative
tracings of the absorbance (measured at 254 nm) in sucrose gradient fractions.
Fractions corresponding to the polysomes were pooled for downstream analyses. B. Ct
values of miR-9-5p following RT-qPCR using nuclear, cytoplasmic, and polysomes
fractions from IVB cells. (N=1)

CHAPTER SIX
FINAL DISCUSSION
Circulating hormones such as E2 can exert pleiotropic effects on various aspects
of human physiology. As such, it is critical for their regulatory potential to be understood
within different cellular contexts. Aging represents a cellular context that is subject to
oxidative stress, DNA damage, and organelle dysfunction (DiLoreto et al., 2015).
Therefore, the molecular actions of E2 must be elucidated within the context of aging to
fully understand the disparate effects of hormone replacement therapy in menopausal
women. In this dissertation, we have identified E2 as a posttranscriptional regulator of
small noncoding RNAs called miRNAs. This novel discovery revealed that E2 can
stabilize mature (22-23 nucleotide) miRNAs in the central nervous system. Furthermore,
this stabilization was dependent on the age of administration; when E2 treatment was
administered at an advanced age, this level of stabilization was no longer evident.
Moreover, E2 mediated stabilization was miRNA specific: miR-9-3p, but not miR-9-5p,
was stabilized in the hypothalamus. These findings are clinically relevant as both of
these miRNAs are neuronally enriched and necessary for the maintenance of neuronal
homeostasis (Jang et al., 2016, Xue et al., 2016). Therefore, the differential stabilization
of miR-9-3p could contribute to the disparate phenotypic effects of HRT in the female
brain. Moreover, it was found that miR-9-3p, which is canonically thought to be the
passenger strand, exhibited a longer half-life than miR-9-5p, the corresponding guide
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strand. The different degradation kinetics of these miRNAs were dependent on
sequence elements found at the 5’ and 3’ ends of the mature miRNA. Furthermore,
miR-9-5p and miR-9-3p associated with distinct proteins, implicating trans factors in the
differential stability of the miRNAs. These novel findings contribute to the current
understanding of miRNA degradation in the central nervous system.
Final Thoughts
MiRNAs are an Attractive Candidate to Underlie the Switch in E2 Action
miRNAs are master regulators of gene expression, as they can potentially
regulate the translation of hundreds of downstream mRNAs (Friedman et al., 2009). As
such, they are evolutionarily integrated in cellular signaling processes necessary for
normal physiological function. Therefore, uncontrolled regulation of these master
regulators themselves has the potential to disrupt the cellular homeostasis of multiple
physiological systems. Additionally, recent evidence suggests that the gene regulatory
functions of miRNAs could be even more robust than previously considered. During the
biogenesis of miRNAs, alternative forms of mature miRNAs can be produced by
differential enzymatic cleavage, RNA editing, and 3’ end modifications such as tailing
and trimming (Bofill-De Ros et al., 2019). These alternative miRNAs, or isomiRs, have
been shown to target separate populations of downstream mRNA targets, unveiling
novel regulatory networks that can arise from a single miRNA. To further add to the
complexity of miRNA regulation, miRNA localization itself can vary—they have been
identified in virtually every subcellular compartment (Katz et al., 2016, Leung et al.,
2015). While the functional implications of differential localization are still the focus of
ongoing research, it seems evident that miRNA function would change based on the
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subcellular compartment in which it is found. In support of this notion, nuclear miRNAs
have been shown to be involved in processes distinct from its cytosolic functions of
translational repression—namely in epigenetic programming and chromatin remodeling
(Katz et al., 2016). Furthermore, evidence of miRNA-mediated transcriptional regulation
has also been observed, further amplifying the regulatory potential of these small
noncoding RNAs. As such, miRNAs represent an attractive candidate to explain the
mechanistic switch in the E2 action as postulated by the Timing Hypothesis. Both the
beneficial and detrimental effects of E2 are far reaching in regard to their manifestations
in various systems, primarily in cardiac and neuronal physiology. Furthermore, miRNAs
have been shown to be critical regulators of both cardiac and neuronal function (Van
Rooji et al., 2007, Xue et al., 2016); therefore, if a subset of these miRNAs were found
to be hormone responsive, they would represent a likely molecular intermediary in the
disparate clinical endpoints observed based on the timing of HRT.
To that end, several neuronally enriched miRNAs have been shown to be
responsive to E2 therapy. While this dissertation has primarily focused on the regulation
of miR-9-5p and miR-9-3p, it is important to consider the 5 other miRNAs that were
found to be regulated by both E2 and age in the rat hypothalamus: let-7i, miR-7a, miR125a, miR-181a, miR-495 (Rao et al., 2013; see Appendix B for degradation kinetics).
Therefore, it is likely that the phenotypic effects of E2 are not mediated solely by miR-95p and miR-9-3p, but rather the culmination of all of these miRNAs. Furthermore, in the
rat ventral hippocampus, an entirely different subset of miRNAs and mRNAs were found
to be altered with age and E2 treatment (Appendix C), underscoring the brain region
specific effects of E2.
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E2 regulation of these miRNAs is likely occurring at different levels of biogenesis.
In IVB cell lines, only miR-181a and miR-9-3p were stabilized at the mature level by E2
treatment (Kim et al., 2020; unpublished master’s thesis), suggesting that the other E2
responsive miRNAs were either regulated at the level of transcription or processing.
Nevertheless, these miRNAs represent focal regulatory nodes within a delicate, yet
complex signaling network composed of bifurcating pathways and feedback
mechanisms. Disruptions to these critical nodes of regulation by nuclear receptor
signaling pathways would inevitably alter cellular homeostasis, which could in turn
manifest in pathological phenotypic endpoints including neuronal apoptosis, synaptic
loss, and at the organismal level—dementia and cognitive dysfunction.
E2 Regulation of MiRNA Degradation is Likely a Multifaceted Process
E2 regulation of miRNA can theoretically occur at every step of the miRNA
biogenesis pathway. For the purposes of this dissertation, the E2 responsive regulation
of miRNA turnover and stability was observed for 2 specific miRNAs: miR-181a and
miR-9-3p (Kim et al., 2020; unpublished master’s thesis). Moreover, this mode of
regulation was not evident for all endogenous neuronal miRNAs, indicating a level of
specificity imparted by E2 signaling. Due to the robustness of nuclear receptor signaling
processes—namely in their capacity to elicit both genomic and nongenomic effects—
this specificity can be achieved in multiple ways.
Perhaps the most parsimonious interpretation for the specific stabilization of
miRNAs can be explained by the genomic actions of E2. Upon binding to its cognate
ligand, it is conceivable that estrogen receptors are recruited to the genome to initiate
the transcription of molecular factors that regulate the stability of a subset of miRNAs.
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These molecular factors are not likely to be proteins in the miRNA biogenesis pathway,
as previously we have shown that the expression of Drosha, Dicer, Dgcr8, Expo5,
Ago2, and Xrn2 are not altered by E2 treatment in both cell lines and in the rat brain
(Chapter 4). Furthermore, all of these proteins have been shown to globally process
most miRNAs, so a disruption to their abundance, or even enzymatic activity, would fail
to explain the specificity of E2 treatment. Therefore, the identity of a protein molecular
factor is likely to be an RNA binding protein (RBP), which has specific RNA recognition
motifs (RRMs). As such, we tested the possibility of SRSF2 as a potential molecular
link, as it was found in our initial screen to be responsive to E2, while also harboring a
recognition motif to a sequence embedded within mature miR-9-3p. Upon further
validation, it was discovered that SRSF2 protein expression was not altered by E2
treatment, and miR-9-3p was undetectable among the RNAs immunoprecipitated with
SRSF2 protein (Chapter 4). However, these results do not preclude the involvement of
other RBPs in providing the specificity of E2-mediated stabilization. One particularly
appealing feature of an RBP molecular link is that it would allow for the prediction of
other hormone responsive miRNAs based on their sequence determinants.
The most intriguing molecular factors, however, are other endogenous RNAs,
especially in light of the recent evidence of target mediated miRNA degradation
(TDMD). It is theoretically possible that E2 bound nuclear receptors could regulate the
transcription of specific mRNAs that could serve as endogenous substrates of TDMD.
However, endogenous substrates for TDMD are relatively scarce due to the extensive
complementarity requirements at the 3’ region of the miRNA. In mammalian systems,
most miRNA: mRNA interactions have several mismatched nucleotides, and these
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types of mismatched interactions are canonically stabilizing, rather than destabilizing,
for the mature miRNA, as it allows for the miRNA 5’ and 3’ end to remain embedded
into Ago2. Therefore, it follows logically that increasing the abundance of target mRNAs
would result in stabilization of the miRNA counterpart. For instance, SIRT1 mRNA
(silent mating type information regulation 2 homolog-1) could be a potential molecular
mediator between the E2 signaling pathway and miRNA stabilization. Specifically,
ligand bound ERα has been shown to bind to the promotor of SIRT1 to upregulate
transcription (Elangoyan et al., 2011); additionally, the miR-9 family has been shown to
directly interact with multiple sites in the 3’ UTR of SIRT1 (Zhou et al., 2017). Therefore,
the E2-mediated upregulation of SIRT1 transcription would augment the availability of
potential miR-9 family target sites, leading to stabilization within the RNA-induced
silencing complex (RISC). In this model of RNA-mediated stabilization, specificity would
similarly be attained by base pairing to specific nucleotide sequences within the target
mRNA.
However, it is important to consider the ramifications of an RNA model,
especially due to the relative abundance of target mRNAs compared to endogenous
miRNAs. The cytoplasmic milieu, therefore, represents many competing RNA sites for
miRNA binding, implying that E2 mediated changes to target mRNA transcription must
be robust enough to overcome this unbalanced stoichiometry. Additionally, upregulation
of transcription alone is but an initial step, as the nascent RNA must be processed,
modified, and transported out of the nucleus, before it can even encounter its cognate
miRNA. Depending on the cellular state, the exported mRNA could also be intertwined
in other regulatory networks distinct from E2 signaling, perhaps unveiling the most

112
enigmatic aspect of this whole process: the ability of the mRNA target to pinpoint the
localization of its miRNA counterpart among other competing cytosolic components.
Whether this process is due to stochiometric probability or due to an active and directed
process, it is evident that in order for E2 to elicit target mediated stabilization, the
amplitude of change—for a single mRNA target—must be substantial. Therefore, it
seems more likely that the E2-mediated stabilization of miRNA is not achieved through
just one mRNA target, but rather by a host of targets. Each miRNA has hundreds of
potential targets, and likewise, estrogen receptors can regulate hundreds of
downstream mRNAs. Therefore, largescale alterations to the cytosolic mRNA milieu
would afford not only specificity, but differential levels of miRNA stabilization depending
on the number of target mRNAs that were altered. Furthermore, modest changes to
multiple mRNA targets could have an additive effect whereby the threshold of
stabilization could ultimately be reached.
To add another layer of complexity, miRNAs are not only the targets of E2
signaling processes, but they, in turn, can regulate estrogen receptor pathways.
Currently, 8 miRNAs have been identified to regulate ERα (miR-18a, miR-18b, miR-22,
miR-221, miR-222, miR-206, miR-193b, miR-302c) and 1 miRNA has been identified to
regulate ERβ (miR-92) (Klinge et al., 2012). Apart from direct inhibition of the estrogen
receptors, other miRNAs such as miR-27b has been observed to reduce levels of
CYP1B1 (Nakajima et al., 2011), which is responsible for the hydroxylation of both E1
and E2, presumably disrupting metabolic processes. Furthermore, miRNAs can also
alter ER function by inhibiting coregulators that normally would be recruited to modify
chromatin structure in an E2 dependent manner. For example, miR-17-5p was found to
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inhibit the translation of steroid receptor coactivator 3 (SRC3) (Hossain et al., 2006).
Likewise, miR-206 reduced levels of steroid receptor coactivator 1 (SRC1) in MCF-7
cells (Adams et al., 2009), again supporting the notion that ER activity can also be
regulated by miRNAs. Therefore, when considering the mechanism of E2-mediated
miRNA stabilization, the counterregulatory potential of miRNAs must also be taken into
account.
MiRNA Stabilization Could Impact Downstream Signaling Processes
Given the extremely rapid half-lives observed for neuronal miRNAs (Appendix B),
it stands to reason that stabilization of these transient regulators could significantly
modify downstream signaling processes. Therefore, dysregulation to miR-9-3p targets
as a consequence of miRNA stabilization—which was observed in both cell lines and in
an animal model of menopause—is likely to underlie the detrimental phenotypes that
was dependent on age of E2 administration. Therefore, the identities of these targets
are of utmost importance. Unfortunately, miRNA: target prediction software such as
TargetScan and myMIR are limited to sequence complementarity analyses; they lack
information concerning cell type specific regulation, 3’ UTR site availability based on
differential secondary structure, and competition with other RNA binding proteins.
Therefore, these predictions must be experimentally confirmed by cloning in the 3’ UTR
of the mRNA target to a luciferase reporter construct to verify that the luciferase activity
is decreased following co-transfection with the miRNA of interest. However, these
experiments are often performed in unrelated cell types for ease of transfection, and the
stoichiometry of both miRNA and 3’UTR target is often skewed due to overexpression.
Analyses of miRNA knockouts and correspondingly de-repressed targets are
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informative, but a direct interaction between miRNA and target cannot be confirmed.
Therefore, the most definitive approach to validate a miRNA target is to mutate the
miRNA binding site at the 3’ UTR and examine the extent to which the phenotype of the
de-repressed target resembles the miRNA knockout. However, these tests in
conjunction are rarely performed due to the extensive nature of this type of examination.
Furthermore, due to the relatively recent discovery of miR-9-3p function—as the
passenger strand was previously thought to be functionally inconsequential—few
validated targets have yet to emerge, especially in the context of the central nervous
system. Recently, miR-9-3p has been shown to have a tumor suppressor function by
targeting homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like
domain member 1 protein (Herpud1) in glioma cells (Yang et al., 2017). Considering
that miR-9-3p is necessary for neuronal differentiation in neural progenitor cells along
with its known regulatory function in modulating synaptic plasticity in post-mitotic
neurons (Sim et al., 2016), it is likely that more miR-9-3p targets will emerge in the near
future. Further research to examine the extent to which these targets are repressed
upon E2-mediated stabilization of miR-9-3p is warranted to understand the molecular
consequences of miRNA stabilization in the brain.
Furthermore, if E2 treatment is unable to sufficiently stabilize neuroprotective
miRNAs when administered too late following the onset of menopause, a clinical
alternative may be to directly administer miRNA mimics in such situations. While RNA
therapeutics are still a developing industry, modifications to the miRNA backbone can
be made to artificially stabilize their half-lives to the days to weeks timescale. Of course,
their enhanced stability, in conjunction with the challenge of engineering neuron specific
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mimics, are also a major concern as to not elicit unwanted side effects. Therefore, the
appropriate dosage and mode of delivery must be meticulously reviewed prior to any
legitimate consideration. Nevertheless, small RNA therapeutics remain an exciting
avenue for future clinical research due to the immense regulatory potential of
endogenous RNAs.
Future Directions
Thus far, evidence has been provided for the E2 mediated stabilization of specific
miRNAs. Furthermore, the subcellular localization of these miRNAs has been shown to
be altered with E2 treatment. However, the causal link between subcellular localization
and stability have yet to be determined. A critical limitation of the biochemical assays
that were utilized in this dissertation is that the subcellular organization cannot be
maintained during the lysis process. However, there are experimental modifications that
can be made to the protocol to isolate specific compartments of interest incorporating
subcellular fractionation prior to the lysis process. The degradation assays can then be
performed using these different subcellular fractions to examine how miRNA stability
can vary within different cellular compartments.
The cellular compartments of interest can even be extracellular in nature.
Numerous reports have identified the presence of miRNAs in circulating exosomes (see
Review: Zhang et al 2015). Exosomes are released from the cell into the circulation
through fusion of intracellular bodies with the plasma membrane. Therefore, miRNAs
that were packaged in these multivesicular bodies are protected from extracellular
RNases, which would presumably extend their half-lives. While it has been proposed
that extracellular miRNAs could have a functional role in intercellular communication,
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the relatively low concentrations of exosomal miRNAs make this claim controversial.
First, these miRNAs, once taken up by the target cell, must compete with host miRNAs
for loading onto Ago2. However, the probability of this event is reduced with such low
starting concentrations. Interestingly, some exosomal miRNAs have been found to be
already loaded into Ago2, potentially bypassing the competition of loading after being
endocytosed in the target cell. Nevertheless, it still seems unlikely that these lowly
abundant miRNAs could vastly alter the cellular landscape of the host. Even in studies
that show exosomal effects on target cells, it is difficult to distinguish the contribution of
exosomal miRNAs from the plethora of other exosomal cargoes that are present.
However, this does not preclude exosomal miRNAs from having any utility; their stable
half-lives in circulation are beneficial for implementation as biomarkers of specific
disease states. Recently, extracellular miRNAs were observed to be viable biomarkers
of age-related cognitive decline (Rani et al., 2017). Therefore, in the context of hormone
replacement therapy, the circulating miRNA profile could be a clinical indicator for the
efficacy of treatment.
Finally, phase separated intracellular compartments, or membrane-less
organelles, are also of interest, particularly due to a recent report describing the
molecular condensation tendencies of Ago2 (Sheu-Gruttadauria et al., 2018),
implicating miRNA regulation to the emerging field of ribonucleoprotein (RNP)
condensates. These discrete cytoplasmic loci are highly dynamic, exchanging both RNA
and protein components depending on the external stimuli. The current understanding is
that RNA induced silencing complexes (RISC) can nucleate processing bodies (Pbodies), and the regulation of target mRNA decay occurs within these defined cytosolic
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loci. This raises the likelihood that miRNA activity and function can be regulated at the
level of P-body assembly and nucleation, which would provide yet another regulatory
step for estrogen signaling. These fundamental mechanisms concerning hormonal
regulation of RNA biology will undoubtedly inform future considerations for estrogen
administration in the aging female brain.

CHAPTER SEVEN
GENERAL METHODS
Animals
Female rats (Wistar, 5 months old; Fisher344, 18 months old, NIH aging colony)
were obtained from Charles River Laboratories. Previous studies showed that miR-9-5p
and miR-9-3p steady-state expression increased with age in the rat hypothalamus and
ventral hippocampus (Rao et al., 2013). Therefore, in this study, we used old (18month) Fisher344 rats. Rats were pair-housed on arrival and allowed to acclimate for 1
week prior to further experimentation. Rats were supplied with standard rat chow and
tap water ad libitum, and animals were kept on a 12:12 light/dark cycle with ZT0 at
7:00 AM. Animals were ovariectomized (OVX) at 18 months of age after the acclimation
period and then left undisturbed for 1 or 12 weeks following OVX. These animal
procedures were followed as outlined by Rao and colleagues (2013). After the
designated time intervals post OVX, the animals were given a subcutaneous injection of
either safflower oil or 2.5 ug/kg 17b-estradiol (E2) dissolved in safflower oil once/day for
3 consecutive days. This dose has been previously reported to achieve circulating
E2 concentrations within the physiological range for postmenopausal women receiving
HRT (17-75 pg/ml) (Schmidt et al., 1994; Rao et al., 2015). The animals
were then anesthetized and euthanized by rapid decapitation 24 hours following the last
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E2 injection. All animal protocols were approved by Loyola University Chicago Animal
Care and Use Committee (IACUC, permit 2009018). Experiments were conducted in
accordance to the guidelines set forth by the IACUC, and all appropriate measures were
taken to minimize pain and suffering.

Ovariectomy
Animals were deeply anesthetized with vaporized isoflurane and
bilaterally ovariectomized (OVX) as described previously (Rao et al., 2015). Briefly, the
ovary along with the distal end of the uterine horn were excised from the body
cavity after the uterine horn was clamped with a hemostat and ligated proximal to the
clamp. Animals were singly housed and provided with acetaminophen analgesic in tap
water for 3 days following the procedure. After 3 days of analgesia, the animals
were pair-housed with their previous cage mate for the duration of the experiment.
Cell Culture
IVB cells, a neuronal cell line derived from rat hypothalamus (provided by John
Kaskow, University of Cincinnati), were grown to 70~80% confluency in Dulbecco’s
Minimum Essential Medium (DMEM) media containing glucose, L-glutamine, sodium
pyruvate, and 10% fetal bovine serum (FBS). Cells were subsequently lysed using a
0.5% NP40 buffer with protease and phosphatase inhibitors (Thermo Fisher Scientific,
#PI88669). Following cell lysis, protein concentration was determined using a BCA
assay according to manufacturer instructions (Thermo Fisher Scientific, #23225).
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Actinomycin Treatment
IVB cells were treated with actinomycin D (Sigma Aldrich, A9415) at a final
concentration of 10 µg/mL for 2 hours in order to inhibit transcription. Actinomycin D
was diluted in dimethyl sulfoxide at a stock concentration of 1 mg/mL prior to addition to
cell culture media. Cells were lysed at three different time points: T0, 15 min., and 60
min. These experiments were performed independently using 5 different cell passages.
RNA isolation and cDNA synthesis
Total RNA was isolated from IVB cells using the Zymogen DirectZol Kit. 1.0 µg of
RNA was reversed transcribed using the Norgen miRNA cDNA Synthesis Kit (#54410)
according to manufacturer instructions.
RT-qPCR
RT- qPCR for miR-9-5p and -3p was performed using forward primers specific to
the mature sequence and a Universal Reverse Primer provided by the Norgen miRNA
cDNA Synthesis Kit (#54410). All reactions were performed in triplicate. 18s rRNA was
used as a loading control to normalize the data for Ct analysis. The following cycling
conditions were used: 1) 95 °C for 10 minutes, 2) 95 °C for 15 seconds, 3) 59 °C for 20
seconds, 4) 72 °C for 12 seconds, and melting curve analysis.
RT- qPCR for miRNA biogenesis enzymes and miR targets were performed
using the procedures and primers previously published by the lab (Rao et al., 2015) All
reactions were performed in triplicate; 18s rRNA was used as a loading control to
normalize the data for ΔΔCt analysis. The following cycling conditions were used: (1)
95°C for 10 min, (2) 95°C for 15 s, (3) 59°C for 20 s, and (4) 72°C for 12s in addition
to melting curve analysis.
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Primary Astrocytes
Primary astrocytes were obtained from the cortex of 5-month-old, female Wistar
rats (N = 3). Cortical tissue was digested using 0.25% trypsin-EDTA, and neuronal cell
growth was inhibited with the addition of DMEM: F12 media supplemented with 0.1
mg/mL primocin following the plating procedure. Primary astrocytes were grown to
70~80% confluency in the following astrocyte medium: Dulbecco’s Minimum Essential
Medium (DMEM) 50:50 F12 media containing glucose, L-glutamine, sodium pyruvate,
and 10% fetal bovine serum (FBS).
Tissue Preparations
18 month old female Fisher 344 rats were killed (N = 3), and whole brain was
isolated and flash frozen in 2-methylbutane at -30C. Flash frozen brains were
sectioned at 200 µm on a freezing microtome, and regions of interest were
microdissected using a 0.75 mm Palkovit’s brain punch tool (Stoelting Co., Wood Dale,
IL; [POA: preoptic area (-.26 to -1.4 mm relative to bregma), SON: supraoptic nucleus
(-.8 to -3.14 mm relative to bregma), vHIPP: ventral hippocampus, (-4.16 to -5.8 mm
relative to bregma)] utilizing The Rat Brain in Stereotaxic Coordinates (Academic Press,
1986) as a reference. Brain tissue lysate was prepared as described above. Selected
samples from the SON brain tissue lysate were treated with 250 μg/mL proteinase K
(ThermoFisher Scientific, #25-530-049) and incubated for 1 hour at 60°C before using in
the miR degradation assay.
MiR Degradation Assay
The miR degradation assay was adapted for tissue and whole cell lysates based
on methods described by Chatterjee and colleagues (Chatterjee et al., 2009). Briefly,
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oligonucleotide constructs were synthesized with the exact nucleotide sequence of the
mature transcript for miR-9-5p and miR-9-3p, [UCUUUGGUUAUCUAGCUGUAUGA]
[AUAAAGCUAGAUAACCGAAAGU], respectively (Integrated DNA Technologies,
Coralville, IA). These single stranded oligonucleotide sequences were then radiolabeled
on the 5’ end using [γ32P] ATP (3000 Ci/mmol) (Perkin Elmer, Waltham, MA). 10 fmols
of the newly radiolabeled sequence was then incubated with 20 µg of protein from either
the IVB cell lysate or brain tissue lysate prepared as described above. Incubation of the
radiolabeled miR with the lysate was terminated at 5 different time points by boiling at
95°C for 2 min. following the addition of 2X RNA Loading Dye (New England Biolabs,
#B0363S). The resulting mixture was then resolved on an 8% urea gel by
electrophoresis.
Finally, the gel was visualized by phosphoimaging (GE Healthcare, Typhoon) to
detect levels of the radiolabeled miR at the various time points. Gel bands were
quantified using densitometry analyses with ImageJ (RRID:SCR_003070) software and
averaged densitometry values from multiples replicates were plotted on a scatterplot
using OriginLab software. Degradation kinetics were determined using a best-fit
exponential decay function.
AGO2 Immunoprecipitation
20 µg of IVB protein lysate was premixed with anti-AGO2, anti-AGO4, β-actin, or IgG
antibody (Wako #22023, RRID:AB_1106837; Cell Signaling #6913,
RRID:AB_10828811; Cell Signaling #4970, RRID:AB_2223172; Millipore #12-370,
RRID:AB_145841) overnight at 4°C. The preformed antibody-antigen complex was then
added to 50 µl of PureProteome Protein A/G Magnetic Beads (Millipore,
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#LSKMAGAG02) and incubated for 30 min. at room temperature. Next, 10 fmols of
radiolabeled miR were added to this mixture and incubated at 37°C for 15 min. The
PureProteome magnetic stand was used to capture the beads, and three washes were
performed with PBS containing 0.1% Tween 20 detergent. After the last wash, the
bound protein complexes were eluted with the addition of 0.5% NP40 buffer and 2X
RNA Loading Dye (New England Biolabs, #B0363S) followed by boiling at 95°C for 2
min.
RNA Immunoprecipitation
500 μg of vHipp lysate, 1 μg of biotinylated RNA (Integrated DNA Technologies,
Coralville, IA), 10X protease inhibitor (ThermoFisher Scientific, #PI88669), 40U/μL
RNase inhibitor (ThermoFisher Scientific, #10-777-019), and 2X TENT buffer (20mM
Tris-HCl, 2mM EDTA, 500mM NaCl, 1% Triton X-100) were mixed and incubated at
room temperature for 30 min. RNA-protein interactions were fixed using formaldehyde
at a 1% final concentration for 10 min. 50 μL of Dynabeads MyOne Streptavidin C1
(ThermoFisher Scientific, #65002) was then added to the above mixture and incubated
for another 30 min. at room temperature. This mixture was placed on a PureProteome
magnetic stand, (Millipore Sigma, #LSKMAGS08) and the beads were washed 3 times
with 1X TENT buffer before final elution with 40 μl of 1X laemmli buffer (Bio-Rad, #1610747) at 95°C for 5 min. The eluted proteins were then run on a 10% SDS PAGE gel at
120 mV for 60 min. and proteins were visualized by Coomassie staining (R250).
Nuclear and Cytosolic Fractionation
IVB cells were grown to 70% confluency and lysed with lysis Buffer J (Norgen).
The lysate was then centrifuged at maximum speed for 3 minutes at 4 °C. The
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supernatant, which contains the cytoplasmic RNA, was then separated from the
resulting pellet, which contains the nuclear fraction. The nuclear pellet was further
disrupted using a 25 gauge needle, and RNA from both fractions were purified
according to manufacturer’s instructions using a column-based approach (Norgen). The
final elution was performed with Buffer E (Norgen), and the purified RNA was reversed
transcribed as previously described.
Western Blot
Protein lysate from PVN tissue microdissections were isolated using 0.5% NP40
buffer. Following determination of protein concentration, 30 μg of protein was boiled with
4X Laemmli buffer (BioRad) at 95°C for 5 minutes before being subject to
electrophoresis on a 10% polyacrylamide gel. Following gel electrophoresis at 120V for
1 hour, proteins were transferred to PVDF membranes (Millipore) at 100V for 1 hour at
4°C. Membranes were blocked with a 1:1 solution of TBS and blocking solution (Licor)
for 1 hour at room temperature. Following the blocking procedure, membranes were
incubated with the indicated primary antibody overnight with constant agitation at 4°C.
Membranes were then incubated with 1:1000 secondary antibodies (Licor) for 1 hour at
room temperature. Finally, western blot images were visualized using the Azure imaging
system.
In Solution Digestion
4 volumes of pre-chilled acetone were added to PVN protein and incubated in 20 °C. for 30 minutes. After centrifugation for 10 minutes at 15,000 x g at 4°C, the
supernatant was discarded. 70% acetone was added to the remaining pellet and the
mixture was vortexed until the pellet dispersed. After another centrifugation for 10
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minutes at 15,000 x g at 4°C, the supernatant was once again discarded, and the pellet
was air dried for 5 minutes at room temperature. The dried pellet was resuspended in a
solution containing 8M urea and 400 mM ammonium bicarbonate. Next, 1:25 v/v of
500mM DTT was added, and the resulting solution was incubated at 95°C for 10 min.
Following reduction, 1:2 v/v of 100 mM iodoacetamide was added and incubated in
room temperature for 30 minutes in the absence of light. Next, 1:20 w/w of trypsin
(1μg/1μl) was added to the sample at incubated for 37°C for 15 hours. The trypsinized
peptides were purified using a C18 spin column according to manufacturer’s
instrunctions (Thermo Scientific, #89873).
In Gel Digestion
Protein bands were cut into 1 mm3 pieces and washed with 100 mM ammonium
bicarbonate shaking at 600 RPM for 15 min. at 37°C. The gel pieces were then washed
with a 50:50 100 mM ammonium bicarbonate and acetonitrile solution at 600 RPM for
15 min. at 37°C. The final wash was performed with 100% acetonitrile at the same
conditions as the previous washes. The gel pieces were reduced with 250 mM DTT
(Sigma-Aldrich, #D9779-5G) at 550 RPM for 60 min. at 56°C and subsequently
alkylated with 50 mM iodoacetamide (Sigma-Aldrich, #A3221-10VL) in the dark for 45
min. at room temperature. Finally, 2 μg of MS grade Trypsin (ThermoFisher Scientific,
#PI90057) was added to the gel pieces to digest the protein overnight at 37°C while
shaking at 600 RPM.
Mass Spectrometry
The analysis was carried out on a Dionex Ultimate 3000 RSLCnano coupled to a
LTQ Orbitrap XL (ThermoFisher Scientific). 10 µL of each sample was injected onto the
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column. Mobile phase A was 100% H2O, 0.1% formic acid, and mobile phase B was
80% ACN, 0.08% formic acid. The flow rate was set at 300 nL/min. The column oven
was set at 40°C. A gradient of 5 – 45% mobile phase B was run over 105 min. followed
by a wash cycle and equilibration of the column. Total run time on the HPLC was 138
min. An EASY-spray column (2 μm particle size, 25 cm x 75 µm ID, PepMap C18) was
used to separate the peptides, and an EASY-Spray ionization source was used for
ionization. Data dependent acquisition was carried out with the mass spectrometer. The
first scan was recorded with the Orbitrap followed by 10 subsequent ion trap scans (FTIT detection) on the top 10 most abundant ions. Collision Induced Dissociation (CID)
was used as the activation source with normalized collision energy at 35. Charge state
rejection was enabled for +1 charged ions, and dynamic exclusion was enabled for a list
size of 500 over 30 seconds. The data was analyzed using PEAKS 8.5 software.
Statistics
All statistical analysis was performed using OriginLab software. A two-sample Ttest was performed to compare the mean half-lives of miR-9-5p and miR-9-3p in cell
lines. The actinomycin D experiments were analyzed using a two-way ANOVA with time
and miR construct as the two factors. The brain region specific degradation of miR-9-5p
and -3p was also analyzed using a two-way ANOVA with brain region and miR
construct as the two factors. A one-way ANOVA was performed to compare the mean
densitometry values of the various miR-9-5p constructs at the T1 time point. A Tukey’s
post hoc test was subsequently performed to determine statistically significant
differences between group means. Finally, a two-sample T-test was performed to
compare the mean fold change values of differentially expressed mRNA and proteins
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following vehicle and E2 treatment. All data points are displayed as mean ± SEM, and
statistical significance was noted when P < 0.05.

APPENDIX A
MASS SPECTOMETRY RESULTS COMPARING PROTEINS
FOLLOWING 2 HR AND 15 HR E2 TREATMENT
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Appendix A. Figure 1. 2 HR and 15 HR E2 Treatment Differentially Alters Protein
Expression in the IVB Cell Line. Heat map depicting significantly regulated (p<0.05)
proteins in the IVB hypothalamic cell line following vehicle or E2 treatment (2HR/15HR).
Protein expression is represented using a color code where red and green represents
upregulation and downregulation respectively (N = 2/group).

APPENDIX B
NEURONAL MIRNAS EXHIBIT DISTINCT DEGRADATION KINETICS IN
HYPOTHALAMIC CELL LINES
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Relative densitometry
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Appendix B Figure 1. E2 responsive miRNAs all display distinct half-lives using
IVB cell lysate. Scatterplot of averaged densitometry values normalized to T0 was fit
with a best-fit exponential decay function for each miRNA. (N=4)

APPENDIX C
MIRNA AND TARGET MRNA EXPRESSION ARE SIGNIFICANTLY REGULATED BY
AGE AND E2 IN THE VENTRAL HIPPOCAMPUS
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A.

Appendix C. Figure A. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and early (18MO)
E2 treatment (N=3).
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Appendix C. Figure B. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between early (18MO) E2 and late (21MO) E2
treatment (N=3).
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Appendix C. Figure C. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between early (18MO) E2 and late (21MO) vehicle
treatment (N=3).
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Appendix C. Figure D. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and late (21MO) E2
treatment (N=3).
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Appendix C. Figure E. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and late (21MO)
vehicle treatment (N=3).

139
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Appendix C. Figure F. Volcano plot depicting significantly regulated miRNAs in the
ventral hippocampus comparing between late (21MO) vehicle and late (21MO) E2
treatment (N=3).
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Appendix C. Figure G. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and early (18MO)
E2 treatment (N=3).
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Appendix C. Figure H. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between early (18MO) E2 and late (21MO) E2
treatment (N=3).
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Appendix C. Figure I. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between late (21MO) vehicle and early (18MO) E2
treatment (N=3).
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Appendix C. Figure J. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and late (21MO) E2
treatment (N=3).
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Appendix C. Figure K. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between early (18MO) vehicle and late (21MO)
vehicle treatment (N=3).
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Appendix C. Figure L. Heat map depicting significantly regulated mRNAs in the
ventral hippocampus comparing between late (21MO) vehicle and late (21MO) E2
treatment (N=3).

146

Fold change
Fold change

Fold change

Fold change

M.

Appendix C. Figure M. RT-qPCR validation of miR-181a and its target Gabra1a. 18MO
= 1 week treatment, 21MO = 12 week treatment (N = 4 for vehicle and N = 3 for E2
treatment).
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